Human anti-factor IX/IXa antibodies

ABSTRACT

The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.

The present application is a division of U.S. Ser. No. 09/383,667, filedon Aug. 26, 1999, now U.S. Pat. No. 6,624,295; which claims priorityunder 35 U.S.C. § 119 to provisional application Nos. 60/122,767, filedMar. 3, 1999 and 60/098,233, filed Aug. 28, 1998, both abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to isolation, identification, synthesis,expression and purification of antibodies reactive with factor IX(FIX)/factor IXa (FIXa) and especially the FIX/FIXa Gla domain. Inparticular aspects, the invention provides human antibodies reactivewith the human FIX/FIXa Gla domain. The invention further relates tocompositions, especially pharmaceutical compositions, articles ofmanufacture, and methods of inhibiting the activation of FIX/FIXa andinhibiting FIX/FIXa dependent coagulation.

2. Description of Related Disclosures

Factor IXa is a vitamin K dependent plasma serine protease thatparticipates in both the intrinsic and extrinsic pathways of bloodcoagulation. The NH₂ terminal 43 amino acids (Gla domain) of factor IXaand its zymogen factor IX contain 12 Gla residues formed by the vitaminK-dependent carboxylation of Glu residues. The Gla domain is followed bytwo epidermal growth factor (EGF) type domains, followed by a carboxyterminal serine protease domain.

The Gla domain of FIX/FIXa contains important structural determinantsfor interaction with high affinity binding sites on vascular endothelialcells and platelets (Heimark et al., (1983) Biochem. Biophys. Res.Commun. 111:723–731; Ahmad et al., (1994) Biochem. 33:12048–12055; Ryanet al., (1989) J. Biol. Chem. 264:20283–20287; Toomey et al., (1992)Biochemistry 31:1806–1808; Cheung et al., (1992) J. Bio. Chem.267:20529–20531; Rawala-Sheikh et al., (1992) Blood 79:398–405; Cheunget al., (1996) Proc. Natl. Acad. Sci. USA 93:11068–11073; Prorok et al.,(1996) Int. J. Pept. Prot. Res. 48:281–285; Ahmad et al., (1998)Biochemistry 37:1671–1679). In the presence of Ca⁺⁺ and Mg⁺⁺ theFIX/FIXa Gla domain adopts different conformations. Coagulationreactions, such as FIX/FIXa-mediated activation of FX proceed with highefficiency on the surface of activated platelets (Ahmad and Walsh (1994)Trends Cardiovasc. Med., 4:271–277).

Antibodies that bind the FIX/FIXa Gla domain have been shown to inhibitFIX/FIXa function, such as cell binding (Cheung et al., (1996) supra;clotting activity (Sugo et al., (1990) Thromb. Res. 58:603–614) andFIX/FIXa activation by FXI (Sugo et al., (1990) supra; Liebman et al.,(1987) J. Bio. Chem. 262:7605–7612). Rabbit and murine antibodies toFIX/FIXa have been shown to bind to the C- and N-terminal region of theGla domain (Liebman et al., (1993) Eur. J. Biochem. 212:339–345 and Sugoet al., (1990) Thromb. Res. 58:603–614). Antibodies reactive with humanFIX/IXa have been shown to inhibit the activation of FIX to FIXa andinhibit coagulation in a FIXa dependent assay (Blackburn et al., (1997)Blood 90:Suppl. 1:424a–425a). Active site inhibited FIXa attenuatesthrombosis in vivo (Wong et al., (1997) Thromb. Haemost. 77:1143–1147;Benedict et al., (1991) J. Clin. Invest. 88:1760–1765; Spanier et al.,(1998) J. Thoracic Cardiovasc. Surgery 115:1179–1188).

SUMMARY OF THE INVENTION

The present invention provides isolated antibodies, antibody fragments,especially human antibodies and antibody fragments, reactive with thefactor 1× or factor IXa Gla domain. In preferred aspects the antibodiesor antibody fragments inhibit an activity associated with bloodcoagulation factor 1× or IXa. Advantageously, the antibodies of thepresent invention provide for the preparation of potent pharmaceuticalcompositions comprising the antibodies. The pharmaceutical compositionsprovide for low dose pharmaceutical formulations for the treatment ofacute and chronic thrombotic disorders without compromising normalhemostasis.

In one embodiment, the invention provides an antibody or antibodyfragment that reacts with human factor FIX/FIXa and especially the humanFIX/FIXa Gla domain. Representative antibody fragments include Fv, scFv,Fab, F(ab′)₂ fragments, as well as diabodies and linear antibodies.These fragments may be fused to other sequences including, for example,a “leucine zipper” or other sequence and include pegylated sequences orFc variants used to improve or modulate half-life. Representativeantibodies or antibody fragments comprise threecomplementarity-determining regions (CDRs) referred to herein as CDR1,CDR2 and CDR3. The amino acid sequences of the CDR polypeptides areselected from those of the exemplary antibody fragments 10C12, 11C5,11G9, 13D1, 13H6 and 14H9 and variants thereof. Preferred antibodies areselected from the group consisting of Ab1, Ab2, Ab3, Ab4, Ab5 and Ab6,wherein the CDRs of Ab1–Ab6 correspond to those of 10C12, 11C5, 11G9,13D1, 13H6 and 14H9, respectively.

In one embodiment, the composition of the present invention is anantibody polypeptide and the invention encompasses a composition ofmatter comprising an isolated nucleic acid, preferably DNA, encoding thepolypeptide of the invention. According to this aspect, the inventionfurther comprises an expression control sequence operably linked to theDNA molecule, an expression vector, preferably a plasmid, comprising theDNA molecule, where the control sequence is recognized by a host cellcomprising the vector, as well as a host cell comprising the vector.

The present invention further extends to therapeutic applications forthe antibody compositions described herein. Thus the invention includesa pharmaceutical composition comprising a pharmaceutically acceptableexcipient and an antibody or antibody fragment of the invention. Theinvention includes kits and articles of manufacture comprising theantibody compositions of the invention. Kits and articles of manufacturepreferably include:

-   -   (a) a container;    -   (b) a label on said container; and    -   (c) a composition comprising an antibody or antibody fragment of        the invention contained within said container;        wherein the composition is effective for treating a coagulation        disorder and the optional label on said container indicates that        the composition can be used for treating a coagulopathic        disorder. The kits optionally include accessory components such        as a second container comprising a pharmaceutically-acceptable        buffer and instructions for using the composition to treat a        coagulation related disorder.

Pharmaceutical compositions comprising the antibodies or antibodyfragments can be used in the treatment or prophylaxis of thrombotic orcoagulopathic diseases or disorders and include, for example, methods oftreating a mammal for which inhibiting a FIX/FIXa mediated event isindicated. The methods comprise administering a therapeuticallyeffective amount of a pharmaceutical composition of the invention to themammal. Such indications include, deep venous thrombosis, arterialthrombosis, unstable angina, post myocardial infarction, post surgicalthrombosis, coronary artery bypass graft (CABG), percutaneoustransluminal coronary angioplasty (PTCA), stroke, tumor growth, invasionor metastasis, inflammation, septic shock, hypotension, ARDS, atrialfibrillation and DIC. The compositions of the present invention may alsobe used as an adjunct in thrombolytic therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B: Gla domain sequences. Sequence homology between FIX Gladomains from various species: human, SEQ ID NO:5; canine, SEQ ID NO:2;murine, SEQ ID NO:3 and rabbit, SEQ ID NO:4 (FIG. 1A) and Gla domains ofvarious human coagulation proteins: factor IX, SEQ ID NO:5; factor X,SEQ ID NO:6; factor VII, SEQ ID NO:7; protein C, SEQ ID NO:8 andprothrombin, SEQ ID NO:9 (FIG. 1B). Non-homologous residues areindicated in bold face type.

FIG. 2: V-gene segment usage and CDR sequences of selected scFv.Residues different from those of 10C12 are indicated in bold type. 10C12heavy chain: CDR1, SEQ ID NO:10; CDR2, SEQ ID NO:11, CDR3, SEQ ID NO:12.10C12 light chain: CDR1, SEQ ID NO:13; CDR2, SEQ ID NO:14; CDR3, SEQ IDNO:15. 11C5 heavy chain: CDR1, SEQ ID NO:10; CDR2, SEQ ID NO:16; CDR3,SEQ ID NO: 17. 11C5 light chain: CDR1, SEQ ID NO:13; CDR2, SEQ ID NO:14;CDR3, SEQ ID NO:15. 11G9 heavy chain: CDR1, SEQ ID NO:10; CDR2, SEQ IDNO:18; CDR3, SEQ ID NO:19. 11G9 light chain: CDR1, SEQ ID NO:13; CDR2,SEQ ID NO:14; CDR3, SEQ ID NO:15. 13D1 heavy chain: CDR1, SEQ ID NO:10;CDR2, SEQ ID NO:20; CDR3, SEQ ID NO:12. 13D1 light chain: CDR1, SEQ IDNO:13; CDR2, SEQ ID NO:14; CDR3, SEQ ID NO:15. 13H6 heavy chain: CDR1,SEQ ID NO:21; CDR2, SEQ ID NO:22; CDR3, SEQ ID NO:23. 13H6 light chain:CDR1, SEQ ID NO:24; CDR2, SEQ ID NO:25; CDR3, SEQ ID NO:26. 14H9 heavychain: CDR1, SEQ ID NO:27; CDR2, SEQ ID NO:28; CDR3, SEQ ID NO:29. 14H9light chain: CDR1, SEQ ID NO:30; CDR2, SEQ ID NO:31; CDR3, SEQ ID NO:32.

FIG. 3: Affinities of selected anti-FIX F(ab′)₂ for human FIX/FIXa:Human FIX was coupled to a biosensor chip according to supplier'sdescription (BIAcore Inc., Piscataway N.J.). The affinities werecalculated from the measured association and dissociation constantsusing a BIAcore-2000™ surface plasmon resonance system (PharmaciaBiosensor).

FIG. 4: Binding of scFv to full length FIX. Plates were coated with 10μg/ml of 9E10 anti-C-myc mAb. Serial dilutions of scFv (10 μg/ml to 5ng/ml) were added to each well for one hour followed by biotinylatedfactor IX (1 μg/ml) and streptavidin-HRP.

FIGS. 5A and 5B: Effect of scFv on FIX binding to bovine aorticendothelial cells and on platelet-dependent coagulation. In FIG. 5Aassays were conducted at 4° C. in 100 μl 10 mM Hepes, 137 mM NaCl, 4 mMKCl, 11 mM glucose, 2 mM CaCl₂, 5 mg/ml bovine serum albumin pH 7.5(assay buffer). Monolayers of bovine aortic endothelial (BAE) cells werewashed once with assay buffer without CaCl₂ before use. The scFv werepre-incubated with biotinylated human FIX in 100 μl buffer for one hour,then added to BAE cells for two hours, washed and incubated with 100 μlof 3,3′5,5′-tetramethylbenzidine/H₂O₂ (Kirkgaard & Perry) substrate forten minutes. The reaction was quenched with 100 μl of 1M H₃PO₄ and theoptical density was read at 450 nm. FIG. 5B—Washed human platelets wereactivated by adenosine diphosphate (ADP) and allowed to adhere tocollagen type III before scFv and human recalcified platelet poor plasmawere added. The effect on coagulation was monitored over 90 min. bymeasuring the increase of the optical density at 405 nm. Shown are theeffects of the scFv at a plasma concentration of 500 nM.

FIGS. 6A and 6B: Binding specificity of anti-FIX scFv and F(ab′)₂. Elisaplates were coated with factor IX, factor X, factor VII, prothrombin, orprotein C at 1 μg/ml. ScFv (FIG. 6A) and F(ab′)₂ (FIG. 6B) were added at5 μg/ml and 0.02 μg/ml, respectively, for one hour. This step wasfollowed by addition of biotinylated 9E10 anti-C-myc mAb (2 μg/ml) andthen streptavidin-HRP. Factor IX+serum: scFvs were preincubated for 1hour on ice with FIX-deficient serum (less than 1% Factor IX residualactivity) prior to incubation with FIX coated on plate. All ELISAbuffers contained 2 mM CaCl₂.

FIGS. 7A and 7B. Comparison of two anti-FIX-F(ab′)₂-leu zipper fragmentsin platelet-dependent coagulation assay. Collagen-adherent activatedhuman platelets were incubated with different concentrations of 10C12F(ab′)₂-leu zipper (FIG. 7A) and 13H₆F(ab′)₂-leu zipper (FIG. 7B) andrecalcified human plasma was added to start the coagulation process. Sixdifferent concentrations per antibody were tested, three of which areshown in each graph. Each value represents the mean±SD of 3 independentexperiments. The IC50 values were calculated from inhibition curves,using the OD values at the 100 min. time point with the control value(uninhibited coagulation) set at 100%. 10C12, IC50=59±3 nM; 13H6,IC50=173±43 nM. Open circles: 1000 nM, open squares: 250 nM,diamonds:62.5 nM, filled triangles: 15.6 nM, filled circles: control.

FIG. 8. Inhibition of FIXa-dependent activation of FX by anti-FIXF(ab′)₂-leu zipper. Antibodies were incubated with FIXa, FVIIIa andphospholipids for 20 min. after which FX was added. The rate of FXageneration was calculated after measuring the concentration of FXa atdifferent time points using the chromogenic substrate S2765. Theinhibition by antibodies is expressed as fractional rates (inhibiteddivided by uninhibited rates of FXa generation). The concentrations ofantibodies 10C12 (squares), 13H6 (diamonds) and an irrelevant controlantibody anti-Neurturin (circles) are those in the final reactionmixture with FX.

FIGS. 9A and 9B. Effects of 10C12 F(ab′)₂-leu zipper on activatedpartial thromboplastin time (APTT) and prothrombin time (PT). In FIG. 9Athe antibodies were incubated with human plasma for 10 min. at 37° C.and the APTT and PT were measured on an ACL 300. Shown are the APTT(filled symbols) and PT (open symbols) by 10C12 F(ab′)₂-leu zipper(squares) and 13H₆F(ab′)₂-leu zipper (circles). In FIG. 9B 10C12F(ab′)₂-leu zipper was incubated for 10 min. at 37° C. with plasma ofdifferent species and the APTT and PT were measured on an ACL 300. Shownare the APTT (filled symbols) and PT (open symbols) of human (circles),rat (diamonds), dog (squares) and rabbit plasma (inverted triangles).

FIGS. 10A and 10B: FIX activation by FXIa and by the tissuefactor:factor VIIa (TF:FVIIa) complex. FIX (400 nM) was incubated with10C12 (filled symbols) or a control antibody (NTN: anti-neurturin) (opensymbols) in HBSA-5 mM CaCl₂. FIG. 10A: 1 nM FXIa was added to start thereaction. FIG. 10B: relipidated TF:FVIIa (4 nM:1 nM) (circles) ormembrane TF:FVIIa (150 μg/ml:1 nM) (squares) was added to start thereaction. At defined time intervals reaction aliquots were quenched inEDTA-ethyleneglycol and FIXa amdiolytic activity in each sample wasdetermined after adding FIXa substrate #299. The inhibition of the ratesof FIXa generation were expressed as fractional rates (vi/vo)±SD of 3–4independent experiments.

FIG. 11: Measurement of activated partial thromboplastin time (APTT) andprothrombin time (PT) in plasma of guinea pig and rat. 10C12 was dilutedin citrated plasma of guinea pig and rat. After an incubation of 10min., human relipidated tissue factor (Innovin) or Actin FS were addedto start the PT (open symbols) and APTT (filled symbols) reaction,respectively. The effects on clotting were expressed as foldprolongation of control plasma clotting times. diamonds=guinea pig;circles=rat.

FIG. 12: Effects of 10C12 on cyclic flow variations (CFVs) in guinea pigarterial thrombosis model. 10C12 and controls were given by intravenousbolus administration 15 min. prior to the initiation of CFVs in thecarotid artery. The number of CFVs during a 40 min. period was recordedand the thrombosis index calculated as the ratio of CFVs divided by thenumber of applied pinches. **p≦0.01, ***p≦0.00.1 versus control byMann-Whitney U-test following determination of significant differencesbetween multiple groups in Kruskal-Wallis test.

FIG. 13: Effect of FeCl₃ treatment on carotid artery blood flow in therat. Representative carotid artery blood flow tracings in rats treatedwith either saline or 10C12 prior to placement of a FeCl₃ saturateddisc. Occlusive thrombosis was induced in 10 of 10 control treated ratsand 0 of 5 rats treated with an iv bolus of 2 mg/kg of 10C12.

FIGS. 14A and 14B: Effects of 10C12 and heparin on thrombus formation inthe FeCl₃-induced arterial thrombosis model in the rat. 10C12 andcontrols were given as bolus and heparin as a 100 U/kg bolus followed byinfusion at a rate of 1 U/kg/min 5 min prior to the placement of theFeCl₃-disc onto the exposed artery.

FIG. 14A: The effects on clot weight were quantified by removing andweighing the thrombus 65 min. after drug administration started. FIG.14B: Effects on the duration of vessel occlusion were determined bymeasuring the time periods during which zero-flow occurred followingplacement of the FeCl₃-disc. **p²0.01 versus control by Mann-WhitneyU-test following determination of significant differences betweenmultiple groups in Kruskal-Wallis test.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

Terms used in the claims and specification are defined as set forthbelow unless otherwise specified.

Abbreviations used throughout the description include: FIX for factorIX; FIXa for factor IXa; FXIa for factor XIa; FXa for factor Xa; TF fortissue factor; FVII for zymogen factor VII; FVIIa for factor VIIa; PTfor prothrombin time; APTT for activated partial thromboplastin time.

The term amino acid or amino acid residue, as used herein, refers tonaturally occurring L amino acids or to D amino acids as describedfurther below with respect to variants. The commonly used one- andthree-letter abbreviations for amino acids are used herein (BruceAlberts et al., Molecular Biology of the Cell, Garland Publishing, Inc.,New York (3d ed. 1994)).

An FIX/FIXa mediated or associated process or event, or equivalently, anactivity associated with plasma FIX/FIXa, according to the presentinvention is any event which requires the presence of FIX/IXa. Thegeneral mechanism of blood clot formation is reviewed by Ganong, inReview of Medical Physiology, 13th ed., Lange, Los Altos Calif., pp411–414 (1987); Bach (1988) CRC Crit. Rev. Biochem. 23(4):339–368 andDavie et al., (1991) Biochemistry 30:10363; and the rate of FIX inLimentani et al., (1994) Hemostasis and Thrombosis Basic Principles andClinical Practice, Third Edition, Coleman et al. Eds., LippincottCompany, Philadelphia. Coagulation requires the confluence of twoprocesses, the production of thrombin which induces platelet aggregationand the formation of fibrin which renders the platelet plug stable. Theprocess comprises several stages each requiring the presence of discreteproenzymes and procofactors. The process ends in fibrin crosslinking andthrombus formation. Fibrinogen is converted to fibrin by the action ofthrombin. Thrombin, in turn, is formed by the proteolytic cleavage ofprothrombin. This proteolysis is effected by FXa which binds to thesurface of activated platelets and in the presence of FVa and calcium,cleaves prothrombin. TF-FVIIa is required for the proteolytic activationof FX by the extrinsic pathway of coagulation. FIX is activated by twodifferent enzymes, FXIa (Fujikawa et al., (1974) Biochemistry,13:4508–4516; Di Scipio et al., (1978) J. Clin. Invest., 61:1528–1538;Østerud et al., (1978) J. Biol. Chem. 253:5946–5951) and the tissuefactor:factor VIIa (TF:FVIIa) complex (Østerud and Rapaport (1977) Proc.Natl. Acad. Sci. USA 74:5260–5264). The formed FIXa in complex with itscofactor FVIIIa assembles into the intrinsic Xase complex on cellsurfaces such as platelets and endothelial cells, and converts substrateFX into FXa (Mann et al., (1992) Semin. Hematol. 29:213–226). Thrombingenerated by FXa enzymatic activity, cleaves fibrinogen leading tofibrin formation and also activates platelets resulting in plateletaggregation. Therefore, a process mediated by or associated withFIX/IXa, or an activity associated with FIXa includes any step in thecoagulation cascade from the introduction of FIX in the extrinsic orintrinsic pathway to the formation of a fibrin platelet clot and whichinitially involves the presence FIX/IXa. FIX/FIXa mediated or associatedprocess, or FIXa activity, can be conveniently measured employingstandard assays such as those described herein.

A FIX/FIXa related disease or disorder is meant to include chronicthromboembolic diseases or disorders associated with fibrin formationincluding vascular disorders such as deep venous thrombosis, arterialthrombosis, stroke, tumor metastasis, thrombolysis, arteriosclerosis andrestenosis following angioplasty, acute and chronic indications such asinflammation, septic shock, septicemia, hypotension, adult respiratorydistress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)and other diseases.

The term “FIX” is used to refer to a polypeptide having an amino acidsequence corresponding to a naturally occurring mammalian factor IX or arecombinant IX described below. Naturally occurring FIX includes humanspecies as well as other animal species such as rabbit, rat, porcine,non human primate, equine, murine, and bovine FIX (see, for example,Yoshitake et al., (1985) Biochemistry 24:3736 (human)). The amino acidsequence of the mammalian factor IX/IXa proteins are generally known orobtainable through conventional techniques. The 43 amino acidγ-carboxyglutamic acid (Gla) domains of human, canine, murine and rabbitFIX are listed in FIG. 1.

The term “treatment” as used within the context of the present inventionis meant to include therapeutic treatment as well as prophylactic, orsuppressive measures for the disease or disorder. Thus, for example, theterm treatment includes the administration of an agent prior to orfollowing the onset of a disease or disorder thereby preventing orremoving all signs of the disease or disorder. As another example,administration of the agent after clinical manifestation of the diseaseto combat the symptoms of the disease comprises “treatment” of thedisease. Further, administration of the agent after onset and afterclinical symptoms have developed where administration affects clinicalparameters of the disease or disorder and perhaps amelioration of thedisease, comprises “treatment” of the disease.

Those “in need of treatment” include mammals, such as humans, alreadyhaving the disease or disorder, including those in which the disease ordisorder is to be prevented.

Antibodies or immunoglobulins are, most commonly, heterotetramericglycoproteins of about 150,000 daltons, composed of two identical light(L) chains and two identical heavy (H) chains. Each light chain islinked to a heavy chain by one covalent disulfide bond, while the numberof disulfide linkages varies between the heavy chains of differentimmunoglobulin isotypes. Each heavy and light chain also has regularlyspaced intrachain disulfide bridges. Each heavy chain has at one end avariable domain (V_(H)) followed by a number of constant domains. Eachlight chain has a variable domain at one end (V_(L)) and a constantdomain at its other end; the constant domain of the light chain isaligned with the first constant domain of the heavy chain, and the lightchain variable domain is aligned with the variable domain of the heavychain. Particular amino acid residues are believed to form an interfacebetween the light- and heavy-chain variable domains (Clothia et al.(1985), J. Mol. Biol. 186:651; Novotny and Haber (1985), Proc. Natl.Acad. Sci. U.S.A. 82:4592).

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called complementarity-determining regions (CDRs) orhypervariable regions both in the light-chain and the heavy-chainvariable domains. The more highly conserved portions of variable domainsare called the framework (FR). The variable domains of native heavy andlight chains each comprise four FR regions, largely adopting a β-sheetconfiguration, connected by three CDRs, which form loops connecting, andin some cases forming part of, the β-sheet structure. The CDRs in eachchain are held together in close proximity by the FR regions and, withthe CDRs from the other chain, contribute to the formation of theantigen-binding site of antibodies (see Kabat et al. (1991), Sequencesof Proteins of Immunological Interest, Fifth Edition, National Instituteof Health, Bethesda, Md.). The constant domains are not involveddirectly in binding an antibody to an antigen, but exhibit variouseffector functions, such as participation of the antibody inantibody-dependent cellular toxicity.

Papain digestion of antibodies produces two identical antigen-bindingfragments, called Fab fragments, each with a single antigen-bindingsite, and a residual Fc fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)₂ fragment thathas two antigen-combining sites and is still capable of cross-linkingantigen.

Fv is the minimum antibody fragment which contains a completeantigen-recognition and -binding site. In a two-chain Fv species, thisregion consists of a dimer of one heavy- and one light-chain variabledomain in tight, non-covalent association. In a single-chain Fv species(scFv), one heavy- and one light-chain variable domain can be covalentlylinked by a flexible peptide linker such that the light and heavy chainscan associate in a “dimeric” structure analogous to that in a two-chainFv species. It is in this configuration that the three CDRs of eachvariable domain interact to define an antigen-binding site on thesurface of the VH-VL dimer. Collectively, the six CDRs conferantigen-binding specificity to the antibody. However, even a singlevariable domain (or half of an Fv comprising only three CDRs specificfor an antigen) has the ability to recognize and bind antigen, althoughat a lower affinity than the entire binding site. For a review of scFvsee Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113,Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269–315 (1994).

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab′ fragmentsdiffer from Fab fragments by the addition of a few residues at thecarboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear a free thiol group. F(ab′)₂ antibody fragments originally wereproduced as pairs of Fab′ fragments which have hinge cysteines betweenthem. Other chemical couplings of antibody fragments are also known.

The light chains of antibodies (immunoglobulins) from any vertebratespecies can be assigned to one of two clearly distinct types, calledkappa (κ) and lambda (λ) based on the amino acid sequences of theirconstant domains.

Depending on the amino acid sequence of the constant domain of theirheavy chains, antibodies can be assigned to different classes. There arefive major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, andseveral of these can be further divided into subclasses (isotypes),e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy-chain constantdomains that correspond to the different classes of immunoglobulins arecalled α, δ, ε, γ, and μ, respectively. The subunit structures andthree-dimensional configurations of different classes of immunoglobulinsare well known.

The term “antibody” is used in the broadest sense and specificallycovers single monoclonal antibodies (including agonist and antagonistantibodies) and antibody compositions with polyepitopic specificity.

“Antibody fragments” comprise a portion of an intact antibody, generallythe antigen binding site or variable region of the intact antibody.Examples of antibody fragments include Fab, Fab′, Fab′-SH, F(ab′)₂, andFv fragments; diabodies; any antibody fragment that is a polypeptidehaving a primary structure consisting of one uninterrupted sequence ofcontiguous amino acid residues (referred to herein as a “single-chainantibody fragment” or “single chain polypeptide”); including withoutlimitation (1)single-chain Fv (scFv) molecules (2) single chainpolypeptides containing only one light chain variable domain, or afragment thereof that contains the three CDRs of the light chainvariable domain, without an associated heavy chain moiety and (3)singlechain polypeptides containing only one heavy chain variable region, or afragment thereof containing the three CDRs of the heavy chain variableregion, without an associated light chain moiety; and multi specificantibodies formed from antibody fragments.

The term “monoclonal antibody” (mAb) as used herein refers to anantibody obtained from a population of substantially homogeneousantibodies, i.e., the individual antibodies comprising the populationare identical except for possible naturally occurring mutations that maybe present in minor amounts. Monoclonal antibodies are highly specific,being directed against a single antigenic site. Furthermore, in contrastto conventional (polyclonal) antibody preparations which typicallyinclude different antibodies directed against different determinants(epitopes), each mAb is directed against a single determinant on theantigen. In addition to their specificity, the monoclonal antibodies areadvantageous in that they can be synthesized by hybridoma culture,uncontaminated by other immunoglobulins. The modifier “monoclonal”indicates the character of the antibody as being obtained from asubstantially homogeneous population of antibodies, and is not to beconstrued as requiring production of the antibody by any particularmethod.

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a heavy chain variabledomain (V_(H)) connected to a light chain variable domain (V_(L)) in thesame polypeptide chain (V_(H) and V_(L)). By using a linker that is tooshort to allow pairing between the two domains on the same chain, thedomains are forced to pair with the complementary domains of anotherchain and create two antigen-binding sites. Diabodies are described morefully in, for example, EP 404,097; WO 93/11161; and Hollinger et al.(1993), Proc. Natl. Acad. Sci. USA 90:6444–6448.

The expression “linear antibodies” when used throughout this applicationrefers to the antibodies described in Zapata et al. (1995) Protein Eng.8(10):1057–1062. Briefly, these antibodies comprise a pair of tandem Fdsegments (V_(H)-C_(H)1-V_(H)-C_(H)1) which form a pair of antigenbinding regions. Linear antibodies can be bispecific or monospecific.

A “variant” antibody or antibody fragment, refers to a molecule whichdiffers in amino acid sequence from a “parent” antibody or antibodyfragment amino acid sequence by virtue of addition, deletion and/orsubstitution of one or more amino acid residue(s), in the parentantibody or antibody fragment sequence. For example, the variant maycomprise one or more amino acid substitution(s) in one or more CDR's ofthe parent antibody or antibody fragment. For example, the variant maycomprise at least one, from about one to about ten, or preferably fromabout two to about five, amino acid substitutions in one or more CDR'sof the parent antibody or antibody fragment. Ordinarily, the variantwill have an amino acid sequence having at least 75% amino acid sequenceidentity with the parent antibody heavy or light chain variable domainsequences, more preferably at least 80%, more preferably at least 85%,more preferably at least 90%, and preferably at least 95%. Identity orhomology with respect to this sequence is defined herein as thepercentage of amino acid residues in the candidate sequence that areidentical with the parent antibody residues, after aligning thesequences and introducing gaps, if necessary, to achieve the maximumpercent sequence identity. None of N-terminal, C-terminal, or internalextensions, deletions, or insertions into the antibody sequence shall beconstrued as affecting sequence identity or homology. The variantretains the ability to bind the human FIX Gla domain and preferably hasproperties which are superior to those of the parent antibody. Forexample, the variant may have a greater binding affinity for the humanFIX Gla domain when compared with the parent antibody or antibody fromwhich it is derived. In analyzing such properties, a variant antibody orantibody fragment, such as a Fab form of the variant, is compared to thesame fragment, for example the Fab form, of the parent antibody orantibody fragment. As a further example, a full length antibody form ofthe variant should be compared to a full length form of the parentantibody, since it has been found that the format of the antibody orantibody fragment impacts its activity in the biological activity assaysdisclosed herein. The variant antibody or antibody fragment ofparticular interest herein is one which displays between 2 and ten fold,preferably, at least about 10 fold, preferably at least about 20 fold,and more preferably at least about 50 fold, enhancement in biologicalactivity when compared to the parent antibody. The term variant is meantto include an antibody or antibody fragment having at least qualitativebiological activity in common with a parent antibody or antibodyfragment and which has at least one amino acid substitution in at leastone CDR of the exemplary CDRs described in FIG. 2. The qualitatingbiological activity referred to is selected, without limitation to asingle activity, from the group consisting of i) reactivity with thehuman FIX/FIXa Gla domain, ii) inhibition of activation of FIX by FXIa;iii) inhibition of activation of FIX by tissue factor:factor VIIacomplex; and iv) inhibition of FX activation. Assay systems formeasurement of inhibition of FIX and FX activation are known in the art.In preferred embodiments, the variant of the present invention competeswith a parent antibody or antibody fragments for binding a human FIX/IXaGla domain. Therefore, without limitation to any one theory, qualitatingbiological activity may be defined as the ability to compete with aparent antibody or antibody fragment and in preferred embodimentsthereby inhibit an activity associated with FIX such as its activationor the activation FX. As will be appreciated from the foregoing, theterm “compete” and “ability to compete” are relative terms. Thus theterms, when used to describe the activity of the variant, means avariant that when added in a 10-fold molar excess to a parent antibodyor fragment in a standard binding assay produces at least a 50%inhibition of binding of the parent antibody or fragment. Preferably thevariant will produce at least a 50% inhibition of binding in a 5-foldmolar excess and most preferably at least a 2-fold molar excess. Apreferred variant of the present invention will produce at least a 50%inhibition of binding when present in a 1:1 stoichiometric ratio withthe parent antibody or antibody fragment.

The “parent” antibody or antibody fragment herein is one which isencoded by an amino acid sequence used for the preparation of thevariant. Preferably, the parent antibody or antibody fragment has ahuman framework region and has human antibody constant region(s). Forexample, the parent antibody or antibody is preferably an isolated humanantibody or fragment thereof.

An “isolated” antibody is one which has been identified and separatedand/or recovered from a component of its natural environment.Contaminant components of its natural environment are materials whichwould interfere with diagnostic or therapeutic uses for the antibody,and may include enzymes, hormones, and other proteinaceous ornonproteinaceous solutes. In preferred embodiments, the antibody will bepurified (1) to greater than 95% by weight of antibody as determined bythe Lowry method, and most preferably more than 99% by weight, (2) to adegree sufficient to obtain at least 15 residues of N-terminal orinternal amino acid sequence by use of a spinning cup sequenator, or (3)to homogeneity by SDS-PAGE under reducing or nonreducing conditionsusing Coomassie blue or, preferably, silver stain. Isolatedantibody-includes the antibody in situ within recombinant cells since atleast one component of the antibody's natural environment will not bepresent. Ordinarily, however, isolated antibody will be prepared by atleast one purification step.

The term “epitope tagged” when used herein refers to an antibody fusedto an “epitope tag”. The epitope tag polypeptide has enough residues toprovide an epitope against which an antibody thereagainst can be made,yet is short enough such that it does not interfere with activity of theantibody. The epitope tag preferably is sufficiently unique so that theantibody thereagainst does not substantially cross-react with otherepitopes. Suitable tag polypeptides generally have at least 6 amino acidresidues and usually between about 8–50 amino acid residues (preferablybetween about 9–30 residues). Examples include the flu HA tagpolypeptide and its antibody 12CA5 (Field et al. (1988), Mol. Cell.Biol. 8:2159–2165); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and9E10 antibodies thereto (Evan et al. (1985), Mol. Cell. Biol.5(12):3610–3616); and the Herpes Simplex virus glycoprotein D (gD) tagand its antibody (Paborsky et al. (1990), Protein Engineering3(6):547–553 (1990)). In certain embodiments, the epitope-tag is a“salvage receptor binding epitope”. As used, herein, the term “salvagereceptor binding epitope” refers to an epitope of the Fc region of anIgG molecule (e.g., IgG₁, IgG₂, IgG₃′ or IgG₄) that is responsible forincreasing the in vivo serum half-life of the IgG molecule.

MODES FOR CARRYING OUT THE INVENTION

The invention provides an antibody or antibody fragment comprising aheavy chain variable domain comprising a CDR amino acid sequence of anyof the heavy chain polypeptide CDR amino acid sequences of FIG. 2. Theinvention encompasses a single chain antibody fragment comprising any ofthe heavy chain CDR sequences, with or without any additional amino acidsequence. By way of example, the invention provides a single chainantibody fragment comprising a heavy chain comprising a CDR1, a CDR2 anda CDR3 without any associated light chain variable domain amino acidsequence, i.e. a single chain species that makes up one half of an Fvfragment.

Further provided herein are an antibody or antibody fragment comprisingany of the heavy chain CDR sequences as described above, and furthercomprising a light chain CDR amino acid sequence comprising the aminoacid sequence of a light chain CDR amino acid sequence of FIG. 2. By wayof example, in one embodiment, the invention provides a single chainantibody fragment wherein any heavy chain comprising a CDR1 a CDR2 and aCDR3, and light chain (λc) comprising a λc-CDR1, a λc-CDR2 and a λc-CDR3are contained in a single chain polypeptide species. By way of exampleand not limitation, the single chain antibody fragment is, in aparticular embodiment, a scFv species comprising the heavy chain joinedto the light chain by means of a flexible peptide linker sequence,wherein the heavy chain and light chain variable domains can associatein a “dimeric” structure analogous to that formed in a two-chain Fvspecies. In another embodiment, the single chain antibody fragment is aspecies comprising the heavy chain joined to the light chain by a linkerthat is too short to permit intramolecular pairing of the two variabledomains, i.e., a single chain polypeptide monomer that forms a diabodyupon dimerization with another monomer.

In yet another embodiment, the invention provides an antibody fragmentcomprising a plurality of polypeptide chains, wherein one polypeptidechain comprises any of the heavy chain CDRs of FIG. 2 and a secondpolypeptide chain comprises any of the light chain CDRs of FIG. 2 andthe two polypeptide chains are covalently linked by one or moreinterchain disulfide bonds. In a preferred embodiment, the foregoingtwo-chain antibody fragment is selected from the group consisting ofFab, Fab′, Fab′-SH, Fv, and F(ab′)₂.

The invention also provides an antibody or antibody fragment comprisinga heavy chain variable domain containing any of the CDRs of FIG. 2 andoptionally further comprising a light chain variable domain containingany of the light chain CDRs of FIG. 2, wherein the heavy chain variabledomain, and optionally the light chain variable domain, is (are) fusedto an additional moiety, such as a immunoglobulin constant domain.Constant domain sequence can be added to the heavy chain and/or lightchain sequence(s) to form species with full or partial length heavyand/or light chain(s). It will be appreciated that constant regions ofany isotype can be used for this purpose, including IgG, IgM, IgA, IgD,and IgE constant regions, and that such constant regions can be obtainedfrom any human or animal species. Preferably, the constant domainsequence is human in origin. Suitable human constant domain sequencescan be obtained from Kabat et al. (supra).

In a preferred embodiment, the antibody or antibody fragment comprisesany of the heavy chain CDR amino acid sequences of FIG. 2 in a variabledomain that is fused to a heavy chain constant domain containing aleucine zipper sequence. The leucine zipper can increase the affinityand/or production efficiency of the antibody or antibody fragment ofinterest. Suitable leucine zipper sequences include the jun and fosleucine zippers taught by Kostelney et al. (1992), J. Immunol., 148:1547–1553, and the GCN4 leucine zipper described in the Examples below.In a preferred embodiment, the antibody or antibody fragment comprisesthe variable domain fused at its C-terminus to the GCN4 leucine zipper.

The invention additionally encompasses antibody and antibody fragmentscomprising variant antibody or antibody fragment. Variant antibodies orantibody fragments include any of the foregoing described antibodies orantibody fragments wherein at least one amino acid of a CDR described inFIG. 2 has been substituted with another amino acid. The skilled artisanwill recognize that certain of the amino acids of the CDR's described inFIG. 2 may be substituted, modified and in some cases deleted, toprovide an antibody or antibody fragment with an improved or alteredbiological activity. Variants of the complementarity determining regionsor variants of variable domains comprising the CDR's of FIG. 2 whichexhibit higher affinity for the FIX Gla domain and/or possess propertiesthat yield greater efficiency in recombinant production processes thanthat of the parent antibody or antibody fragment are preferred in thecontext of the present invention.

Methods of Making

Nucleic acid encoding the antibodies or antibody fragments of theinvention can be prepared from a library of single chain antibodiesdisplayed on a bacteriophage. The preparation of such a library is wellknown to one of skill in this art. Suitable libraries may be prepared bythe methods described in WO 92/01047, WO 92/20791, WO 93/06213, WO93/11236, WO 93/19172, WO 95/01438 and WO 95/15388. In a preferredembodiment, a library of single chain antibodies (scFv) may be generatedfrom a diverse population of human B-cells from human donors. mRNAcorresponding to the VH and VL antibody chains is isolated and purifiedusing standard techniques and reverse transcribed to generate apopulation of cDNA. After PCR amplification, DNA coding for single chainantibodies is assembled using a linker, such as Gly₄Ser (SEQ ID NO:1),and cloned into suitable expression vectors. A phage library is thenprepared in which the population of single chain antibodies is displayedon the surface of the phage. Suitable methods for preparing phagelibraries have been reviewed and are described in Winter et. al. (1994),Annu. Rev. Immunol. 12:433–55; Soderlind et. al. (1992), ImmunologicalReviews 130:109–123; Hoogenboom, Tibtech (February 1997), Vol. 15; Neriet. al. (1995), Cell Biophysics 27:47–61, and the references describedtherein.

The antibodies of the invention may be selected by immobilizing a FIXGla domain and then panning a library of human scFv prepared asdescribed above using the immobilized FIX Gla domain to bind antibody.Griffiths et. al. (1993), EMBO-J 12:725–734. The specificity andactivity of specific clones can be assessed using known assays.Griffiths et. al.; Clarkson et. al. (1991), Nature 352:642–648. After afirst panning step, one obtains a library of phage containing aplurality of different single chain antibodies displayed on phage havingimproved binding to the FIX Gla domain. Subsequent panning steps provideadditional libraries with higher binding affinities. When avidityeffects are a problem, monovalent phage display libraries may be used inwhich less than 20%, preferably less than 10%, and more preferably lessthan 1% of the phage display more than one copy of an antibody on thesurface of the phage. Monovalent display can be accomplished with theuse of phagemid and helper phage as described, for example, in Lowmanet. al. (1991), Methods: A Companion to Methods in Enzymology3(3):205–216. A preferred phage is M13 and display is preferably as afusion protein with coat protein 3 as described in Lowman et. al.,supra. Other suitable phage include fl and fd filamentous phage. Fusionprotein display with other virus coat proteins is also known and may beused in this invention. See U.S. Pat. No. 5,223,409.

Amino acid sequence variants of the antibody are prepared by introducingappropriate nucleotide changes into the antibody DNA, or by peptidesynthesis. Such variants include, for example, deletions from, and/orinsertions into and/or substitutions of, residues within the amino acidsequences of the antibodies of the examples herein. Any combination ofdeletion, insertion, and substitution is made to arrive at the finalconstruct, provided that the final construct possesses the desiredcharacteristics. The amino acid changes also may alterpost-translational processes of the variant antibody, such as changingthe number or position of glycosylation sites.

A useful method for identification of certain residues or regions of theantibody that are preferred locations for mutagenesis is called “alaninescanning mutagenesis,” as described by Cunningham and Wells (1989),Science 244:1081–1085 (1989). Here, a residue or group of targetresidues are identified (e.g., charged residues such as arg, asp, his,lys, and glu) and replaced by a neutral or negatively charged amino acid(most preferably alanine or polyalanine) to affect the interaction ofthe amino acids with the FIX Gla domain. Those amino acid locationsdemonstrating functional sensitivity to the substitutions then arerefined by introducing further or other variants at, or for, the sitesof substitution. Thus, while the site for introducing an amino acidsequence variation is predetermined, the nature of the mutation per seneed not be predetermined. For example, to analyze the performance of amutation at a given site, ala scanning or random mutagenesis isconducted at the target codon or region and the expressed antibodyvariants are screened for the desired activity.

Amino acid sequence insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Examples of terminal insertions includean antibody with an N-terminal methionyl residue or the antibody fusedto an epitope tag. Other insertional variants of the antibody moleculeinclude the fusion to the N- or C-terminus of the antibody of an enzymeor a polypeptide or PEG which increases the serum half-life of theantibody.

Another type of variant is an amino acid substitution variant. Thesevariants have at least one amino acid residue in the antibody moleculeremoved and a different residue inserted in its place. The sites ofgreatest interest for substitutional mutagenesis include thehypervariable regions, but FR alterations are also contemplated.Conservative substitutions are shown in Table A under the heading of“preferred substitutions”. If such substitutions result in a change inbiological activity, then more substantial changes, denominated“exemplary substitutions” in Table A, or as further described below inreference to amino acid classes, may be introduced and the productsscreened.

TABLE A Original Exemplary Preferred Residue Substitutions SubstitutionsAla (A) Val; leu; ile val Arg (R) Lys; gln; asn lys Asn (N) Gln; his;asp, lys; arg gln Asp (D) Glu; asn glu Cys (C) Ser; ala ser Gln (Q) Asn;glu asn Glu (E) Asp; gln asp Gly (G) Ala ala His (H) Asn; gln; lys; argarg Ile (I) Leu; val; met; ala; phe; norleucine leu Leu (L) Norleucine;ile; val; met; ala; phe ile Lys (K) Arg; gln; asn arg Met (M) Leu; phe;ile leu Phe (F) Leu; val; ile; ala; tyr tyr Pro (P) Ala ala Ser (S) Thrthr Thr (T) Ser ser Trp (W) tyr; phe tyr Tyr (Y) trp, phe; thr; ser pheVal (V) ile; leu; met; phe; ala; norleucine leuSubstantial modifications in the biological properties of the antibodyare accomplished by selecting substitutions that differ significantly intheir effect on maintaining (a) the structure of the polypeptidebackbone in the area of the substitution, for example, as a sheet orhelical conformation, (b) the charge or hydrophobicity of the moleculeat the target site, or (c) the bulk of the side chain. Naturallyoccurring residues are divided into groups based on common side-chainproperties:

-   -   (1) hydrophobic: norleucine, met, ala, val, leu, ile;    -   (2) neutral hydrophilic: cys, ser, thr;    -   (3) acidic: asp, glu;    -   (4) basic: asn, gln, his, lys, arg;    -   (5) residues that influence chain orientation: gly, pro; and    -   (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

Any cysteine residue not involved in maintaining the proper conformationof the variant antibody also may be substituted, generally with serine,to improve the oxidative stability of the molecule and prevent aberrantcrosslinking. Conversely, cysteine bond(s) may be added to the antibodyto improve its stability (particularly where the antibody is an antibodyfragment such as an Fv fragment).

A particularly preferred type of substitutional variant involvessubstituting one or more hypervariable region residues of a parentantibody (e.g. a human antibody). Generally, the resulting variant(s)selected for further development will have improved biologicalproperties relative to the parent antibody from which they aregenerated. A convenient way for generating such substitutional variantsis affinity maturation using phage using methods known in the art.Briefly, several hypervariable region sites (e.g. 3–7 sites) are mutatedto generate all possible amino substitutions at each site. The antibodyvariants thus generated are displayed in a monovalent fashion fromfilamentous phage particles as fusions to the gene III product of M13packaged within each particle. The phage-displayed variants are thenscreened for their biological activity (e.g. binding affinity) as hereindisclosed. In order to identify candidate hypervariable region sites formodification, alanine scanning mutagenesis can be performed toidentified hypervariable region residues contributing significantly toantigen binding. Alternatively, or in addition, it may be beneficial toanalyze a crystal structure of the antigen-antibody complex to identifycontact points between the antibody and FIX Gla domain. Such contactresidues and neighboring residues are candidates for substitutionaccording to the techniques elaborated herein. Once such variants aregenerated, the panel of variants is subjected to screening as describedherein and antibodies with superior properties in one or more relevantassays may be selected for further development.

Another type of amino acid variant of the antibody alters the originalglycosylation pattern of the antibody. By altering is meant deleting oneor more carbohydrate moieties found in the antibody, and/or adding oneor more glycosylation sites that are not present in the antibody.

Glycosylation of antibodies is typically either N-linked or O-linked.N-linked refers to the attachment of the carbohydrate moiety to the sidechain of an asparagine residue. The tripeptide sequencesasparagine-X-serine and asparagine-X-threonine, where X is any aminoacid except proline, are the recognition sequences for enzymaticattachment of the carbohydrate moiety to the asparagine side chain.Thus, the presence of either of these tripeptide sequences in apolypeptide creates a potential glycosylation site. O-linkedglycosylation refers to the attachment of one of the sugarsN-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, mostcommonly serine or threonine, although 5-hydroxyproline or5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is convenientlyaccomplished by altering the amino acid sequence such that it containsone or more of the above-described tripeptide sequences (for N-linkedglycosylation sites). The alteration may also be made by the additionof, or substitution by, one or more serine or threonine residues to thesequence of the original antibody (for O-linked glycosylation sites).

Nucleic acid molecules encoding amino acid sequence variants of theantibody are prepared by a variety of methods known in the art. Thesemethods include, but are not limited to, isolation from a natural source(in the case of naturally occurring amino acid sequence variants) orpreparation by oligonucleotide-mediated (or site-directed) mutagenesis,PCR mutagenesis, and cassette mutagenesis of an earlier prepared variantor a non-variant version of the antibody.

Preferably, the antibodies are prepared by standard recombinantprocedures which involve production of the antibodies by culturing cellstransfected to express antibody nucleic acid (typically by transformingthe cells with an expression vector) and recovering the antibody fromthe cells of cell culture.

The nucleic acid (e.g., cDNA or genomic DNA) encoding antibody selectedas described above is inserted into a replicable vector for furthercloning (amplification of the DNA) or for expression. Many vectors areavailable, and selection of the appropriate vector will depend on (1)whether it is to be used for DNA amplification or for DNA expression,(2) the size of the nucleic acid to be inserted into the vector, and (3)the host cell to be transformed with the vector. Each vector containsvarious components depending on its function (amplification of DNA orexpression of DNA) and the host cell with which it is compatible. Thevector components generally include, but are not limited to, one or moreof the following: a signal sequence, an origin of replication, one ormore marker genes, an enhancer element, a promoter, and a transcriptiontermination sequence.

(i) Signal Sequence Component

The antibody of this invention may be expressed not only directly, butalso as a fusion with a heterologous polypeptide, preferably a signalsequence or other polypeptide having a specific cleavage site at theN-terminus of the mature protein or polypeptide. In general, the signalsequence may be a component of the vector, or it may be a part of theantibody DNA that is inserted into the vector. The heterologous signalsequence selected should be one that is recognized and processed (i.e.,cleaved by a signal peptidase) by the host cell. For prokaryotic hostcells a prokaryotic signal sequence selected, for example, from thegroup of the alkaline phosphatase, penicillinase, lpp, or heat-stableenterotoxin II leaders. For yeast secretion the native signal sequencemay be substituted by, e.g., the yeast invertase, alpha factor, or acidphosphatase leaders, the C. albicans glucoamylase leader (EP 362,179published 4 Apr. 1990), or the signal described in WO 90/13646 published15 Nov. 1990. In mammalian cell expression the native signal sequence issatisfactory, although other mammalian signal sequences may be suitable,such as signal sequences from other ligand polypeptides or from the sameligand from a different animal species, signal sequences from a ligand,and signal sequences from secreted polypeptides of the same or relatedspecies, as well as viral secretory leaders, for example, the herpessimplex gD signal.

(ii) Origin of Replication Component

Both expression and cloning vectors contain a nucleic acid sequence thatenables the vector to replicate in one or more selected host cells.Generally, in cloning vectors this sequence is one that enables thevector to replicate independently of the host chromosomal DNA, andincludes origins of replication or autonomously replicating sequences.Such sequences are well known for a variety of bacteria, yeast, andviruses. The origin of replication from the plasmid pBR322 is suitablefor most Gram-negative bacteria, the 2μ plasmid origin is suitable foryeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV)are useful for cloning vectors in mammalian cells. Generally, the originof replication component is not needed for mammalian expression vectors(the SV40 origin may typically be used only because it contains theearly promoter).

Most expression vectors are “shuttle” vectors, i.e., they are capable ofreplication in at least one class of organisms but can be transfectedinto another organism for expression. For example, a vector is cloned inE. coli and then the same vector is transfected into yeast or mammaliancells for expression even though it is not capable of replicatingindependently of the host cell chromosome.

DNA may also be amplified by insertion into the host genome. This isreadily accomplished using Bacillus species as hosts, for example, byincluding in the vector a DNA sequence that is complementary to asequence found in Bacillus genomic DNA. Transfection of Bacillus withthis vector results in homologous recombination with the genome andinsertion of antibody DNA. However, the recovery of genomic DNA encodingantibody is more complex than that of an exogenously replicated vectorbecause restriction enzyme digestion is required to excise the antibodyDNA.

(iii) Selection Gene Component

Expression and cloning vectors should contain a selection gene, alsotermed a selectable marker. This gene encodes a protein necessary forthe survival or growth of transformed host cells grown in a selectiveculture medium. Host cells not transformed with the vector containingthe selection gene will not survive in the culture medium. Typicalselection genes encode proteins that (a) confer resistance toantibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate,or tetracycline, (b) complement auxotrophic deficiencies, or (c) supplycritical nutrients not available from complex media, e.g., the geneencoding D-alanine racemase for Bacilli.

One example of a selection scheme utilizes a drug to arrest growth of ahost cell. Those cells that are successfully transformed with aheterologous gene express a protein conferring drug resistance and thussurvive the selection regimen. Examples of such dominant selection usethe drugs neomycin (Southern et al. (1982), J. Molec. Appl. Genet.1:327) mycophenolic acid (Mulligan et al. (1980), Science 209:1422) orhygromycin (Sugden et al. (1985), Mol. Cell. Biol. 5:410–413). The threeexamples given above employ bacterial genes under eukaryotic control toconvey resistance to the appropriate drug G418 or neomycin (geneticin),xgpt (mycophenolic acid), or hygromycin, respectively.

Examples of other suitable selectable markers for mammalian cells arethose that enable the identification of cells competent to take up theantibody nucleic acid, such as dihydrofolate reductase (DHFR) orthymidine kinase. The mammalian cell transformants are placed underselection pressure that only the transformants are uniquely adapted tosurvive by virtue of having taken up the marker. Selection pressure isimposed by culturing the transformants under conditions in which theconcentration of selection agent in the medium is successively changed,thereby leading to amplification of both the selection gene and the DNAthat encodes antibody. Amplification is the process by which genes ingreater demand for the production of a protein critical for growth arereiterated in tandem within the chromosomes of successive generations ofrecombinant cells. Increased quantities of antibody are synthesized fromthe amplified DNA.

For example, cells transformed with the DHFR selection gene are firstidentified by culturing all of the transformants in a culture mediumthat contains methotrexate (Mtx), a competitive antagonist of DHFR. Anappropriate host cell when wild-type DHFR is employed is the Chinesehamster ovary (CHO) cell line deficient in DHFR activity, prepared andpropagated as described by Urlaub and Chasin (1980), Proc. Natl. Acad.Sci. USA 77:4216. The transformed cells are then exposed to increasedlevels of Mtx. This leads to the synthesis of multiple copies of theDHFR gene, and, concomitantly, multiple copies of other DNA comprisingthe expression vectors, such as the DNA encoding antibody. Thisamplification technique can be used with any otherwise suitable host,e.g., ATCC No. CCL61 CHO-K1, notwithstanding the presence of endogenousDHFR if, for example, a mutant DHFR gene that is highly resistant to Mtxis employed (EP 117,060). Alternatively, host cells (particularlywild-type hosts that contain endogenous DHFR) transformed orco-transformed with DNA sequences encoding antibody, wild-type DHFRprotein, and another selectable marker such as aminoglycoside 3′phosphotransferase (APH) can be selected by cell growth in mediumcontaining a selection agent for the selectable marker such as anaminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S.Pat. No. 4,965,199.

A suitable selection gene for use in yeast is the trp1 gene present inthe yeast plasmid YRp7 (Stinchcomb et al. (1979), Nature 282:39;Kingsman et al. (1979), Gene 7:141; or Tschemper et al. (1980), Gene10:157). The trp1 gene provides a selection marker for a mutant strainof yeast lacking the ability to grow in tryptophan, for example, ATCCNo. 44076 or PEP4-1 (Jones (1977), Genetics 85:12). The presence of thetrp1 lesion in the yeast host cell genome then provides an effectiveenvironment for detecting transformation by growth in the absence oftryptophan. Similarly, Leu2-deficient yeast strains (ATCC No. 20,622 or38,626) are complemented by known plasmids bearing the Leu2 gene.

(iv) Promoter Component

Expression and cloning vectors usually contain a promoter that isrecognized by the host organism and is operably linked to the antibodynucleic acid. Promoters are untranslated sequences located upstream (5′)to the start codon of a structural gene (generally within about 100 to1000 bp) that control the transcription and translation of particularnucleic acid sequence, such as the antibody nucleic acid sequence, towhich they are operably linked. Such promoters typically fall into twoclasses, inducible and constitutive. Inducible promoters are promotersthat initiate increased levels of transcription from DNA under theircontrol in response to some change in culture conditions, e.g., thepresence or absence of a nutrient or a change in temperature. At thistime a large number of promoters recognized by a variety of potentialhost cells are well known. These promoters are operably linked toantibody encoding DNA by removing the promoter from the source DNA byrestriction enzyme digestion and inserting the isolated promotersequence into the vector. Both the native antibody promoter sequence andmany heterologous promoters may be used to direct amplification and/orexpression of the antibody DNA. However, heterologous promoters arepreferred, as they generally permit greater transcription and higheryields of expressed antibody as compared to the native promoter.

Promoters suitable for use with prokaryotic hosts include theβ-lactamase and lactose promoter systems (Chang et al. (1978), Nature275:615; and Goeddel et al. (1979), Nature 281:544), alkalinephosphatase, a tryptophan (trp) promoter system (Goeddel (1980), NucleicAcids Res. 8:4057 and EP 36,776) and hybrid promoters such as the tacpromoter (deBoer et al. (1983), Proc. Natl. Acad. Sci. USA 80:21–25).However, other known bacterial promoters are suitable. Their nucleotidesequences have been published, thereby enabling a skilled workeroperably to ligate them to DNA encoding antibody (Siebenlist et al.(1980), Cell 20:269) using linkers or adapters to supply any requiredrestriction sites. Promoters for use in bacterial systems also willcontain a Shine-Dalgarno (S.D.) sequence operably linked to the DNAencoding antibody polypeptide.

Promoter sequences are known for eukaryotes. Virtually all eukaryoticgenes have an AT-rich region located approximately 25 to 30 basesupstream from the site where transcription is initiated. Anothersequence found 70 to 80 bases upstream from the start of transcriptionof many genes is a CXCAAT region where X may be any nucleotide. At the3′ end of most eukaryotic genes is an AATAAA sequence that may be thesignal for addition of the poly A tail to the 3′ end of the codingsequence. All of these sequences are suitably inserted into eukaryoticexpression vectors.

Examples of suitable promoting sequences for use with yeast hostsinclude the promoters for 3-phosphoglycerate kinase (Hitzeman et al.(1980), J. Biol. Chem. 255:2073) or other glycolytic enzymes (Hess etal. (1968), J. Adv. Enzyme Reg. 7:149; and Holland (1978), Biochemistry17:4900), such as enolase, glyceraldehyde-3-phosphate dehydrogenase,hexokinase, pyruvate decarboxylase, phosphofructokinase,glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvatekinase, triosephosphate isomerase, phosphoglucose isomerase, andglucokinase.

Other yeast promoters, which are inducible promoters having theadditional advantage of transcription controlled by growth conditions,are the promoter regions for alcohol dehydrogenase 2, isocytochrome C,acid phosphatase, degradative enzymes associated with nitrogenmetabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase,and enzymes responsible for maltose and galactose utilization. Suitablevectors and promoters for use in yeast expression are further describedin Hitzeman et al., EP 73,657A. Yeast enhancers also are advantageouslyused with yeast promoters.

Antibody transcription from vectors in mammalian host cells may becontrolled, for example, by promoters obtained from the genomes ofviruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus,avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virusand most preferably Simian Virus 40 (SV40), from heterologous mammalianpromoters, e.g., the actin promoter or an immunoglobulin promoter, fromheat-shock promoters, and from the promoter normally associated with theantibody sequence, provided such promoters are compatible with the hostcell systems.

The early and late promoters of the SV40 virus are conveniently obtainedas an SV40 restriction fragment that also contains the SV40 viral originof replication. Fiers et al. (1978), Nature 273:113; Mulligan and Berg(1980), Science 209:1422–1427; Pavlakis et al. (1981), Proc. Natl. Acad.Sci. USA 78:7398–7402. The immediate early promoter of the humancytomegalovirus is conveniently obtained as a HindIII E restrictionfragment. Greenaway et al. (1982), Gene, 18:355–360. A system forexpressing DNA in mammalian hosts using the bovine papilloma virus as avector is disclosed in U.S. Pat. No. 4,419,446. A modification of thissystem is described in U.S. Pat. No. 4,601,978. See also Gray et al.(1982), Nature 295:503–508 on expressing cDNA encoding immune interferonin monkey cells; Reyes et al. (1982), Nature 297:598–601 on expressionof human β-interferon cDNA in mouse cells under the control of athymidine kinase promoter from herpes simplex virus; Canaani and Berg(1982), Proc. Natl. Acad. Sci. USA 79:5166–5170, on expression of thehuman interferon β1 gene in cultured mouse and rabbit cells; and Gormanet al. (1982), Proc. Natl. Acad. Sci. USA 79:6777–6781, on expression ofbacterial CAT sequences in CV-1 monkey kidney cells, chicken embryofibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3cells using the Rous sarcoma virus long terminal repeat as a promoter.

(v) Enhancer Element Component

Transcription of a DNA encoding the antibody of this invention by highereukaryotes is often increased by inserting an enhancer sequence into thevector. Enhancers are cis-acting elements of DNA, usually about from 10to 300 bp, that act on a promoter to increase its transcription.Enhancers are relatively orientation and position independent, havingbeen found 5′ (Laimins et al. (1981), Proc. Natl. Acad. Sci. USA 78:993)and 3′ (Lusky et al. (1983), Mol. Cell Bio. 3:1108) to the transcriptionunit, within an intron (Banerji et al. (1983), Cell 33:729), as well aswithin the coding sequence itself (Osborne et al. (1984), Mol. Cell Bio.4:1293). Many enhancer sequences are now known from mammalian genes(globin, elastase, albumin, a-fetoprotein, and insulin). Typically,however, one will use an enhancer from a eukaryotic cell virus. Examplesinclude the SV40 enhancer on the late side of the replication origin (bp100–270), the cytomegalovirus early promoter enhancer, the polyomaenhancer on the late side of the replication origin, and adenovirusenhancers. See also Yaniv (1982), Nature 297:17–18, on enhancingelements for activation of eukaryotic promoters. The enhancer may bespliced into the vector at a position 5′ or 3′ to the antibody encodingsequence, but is preferably located at a site 5′ from the promoter.

(vi) Transcription Termination Component

Expression vectors used in eukaryotic host cells (yeast, fungi, insect,plant, animal, human, or nucleated cells from other multicellularorganisms) will also contain sequences necessary for the termination oftranscription and for stabilizing the mRNA. Such sequences are commonlyavailable from the 5′ and, occasionally 3′ untranslated regions ofeukaryotic or viral DNAs or cDNAs. These regions contain nucleotidesegments transcribed as polyadenylated fragments in the untranslatedportion of the mRNA encoding antibody.

(vii) Construction and Analysis of Vectors

Construction of suitable vectors containing one or more of the abovelisted components employs standard ligation techniques. Isolatedplasmids or DNA fragments are cleaved, tailored, and religated in theform desired to generate the plasmids required.

For analysis to confirm correct sequences in plasmids constructed, theligation mixtures are used to transform E. coli K12 strain 294 (ATCC No.31,446) and successful transformants selected by ampicillin ortetracycline resistance where appropriate. Plasmids from thetransformants are prepared, analyzed by restriction endonucleasedigestion, and/or sequenced by the method of Messing et al. (1981),Nucleic Acids Res. 9:309 or by the method of Maxam et al. (1980),Methods in Enzymology 65:499.

(viii) Transient Expression Vectors

Particularly useful in the practice of this invention are expressionvectors that provide for the transient expression in mammalian cells ofDNA encoding the antibody polypeptide. In general, transient expressioninvolves the use of an expression vector that is able to replicateefficiently in a host cell, such that the host cell accumulates-manycopies of the expression vector and, in turn, synthesizes high levels ofa desired polypeptide encoded by the expression vector. Sambrook et al.,supra, pp. 16.17–16.22. Transient expression systems, comprising asuitable expression vector and a host cell, allow for the convenientpositive identification of polypeptides encoded by cloned DNAs, as wellas for the rapid screening of such polypeptides for desired biologicalor physiological properties. Thus, transient expression systems areparticularly useful in the invention for purposes of identifyinganalogues and variants of antibody polypeptide that have antibodypolypeptide biological activity.

(ix) Suitable Exemplary Vertebrate Cell Vectors

Other methods, vectors, and host cells suitable for adaptation to thesynthesis of the antibody in recombinant vertebrate cell culture aredescribed in Gething et al. (1981), Nature 293:620–625; Mantei et al.(1979), Nature 281:40–46; Levinson et al.; EP 117,060; and EP 117,058. Aparticularly useful plasmid for mammalian cell culture expression ispRK5 (EP 307,247 U.S. Pat. No. 5,258,287) or pSVI6B (PCT Publication No.WO 91/08291).

Suitable host cells for cloning or expressing the vectors herein are theprokaryote, yeast, or higher eukaryotic cells described above. Suitableprokaryotes include eubacteria, such as Gram-negative or Gram-positiveorganisms, for example, E. coli, Bacilli such as B. subtilis,Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, orSerratia marcescans. One preferred E. coli cloning host is E. coli 294(ATCC No. 31,446), although other strains such as E. coli B, E. coliX1776 (ATCC No. 31,537), and E. coli W3110 (ATCC No. 27,325) aresuitable. These examples are illustrative rather than limiting.Preferably the host cell should secrete minimal amounts of proteolyticenzymes. Alternatively, in vitro methods of cloning, e.g., PCR or othernucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentousfungi or yeast are suitable hosts for antibody encoding vectors.Saccharomyces cerevisiae, or common baker's yeast, is the most commonlyused among lower eukaryotic host microorganisms. However, a number ofother genera, species, and strains are commonly available and usefulherein, such as Schizosaccharomyces pombe (Beach and Nurse (1981),Nature-290:140; EP 139,383 published 2 May 1985), Kluyveromyces hosts(U.S. Pat. No. 4,943,529) such as, e.g., K. lactis (Louvencourt et al.(1983, J. Bacteriol. 737), K. fragilis, K. bulgaricus, K.thermotolerans, and K. marxianus, yarrowia (EP 402,226), Pichia pastoris(EP 183,070; Sreekrishna et al. (1988), J. Basic Microbiol. 28:265–278),Candida, Trichoderma reesia (EP 244,234), Neurospora crassa (Case et al.(1979), Proc. Natl. Acad. Sci. USA 76:5259–5263), and filamentous fungisuch as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91/00357published 10 Jan. 1991), and Aspergillus hosts such as A. nidulans(Ballance et al. (1983), Biochem. Biophys. Res. Commun. 112:284–289;Tilburn et al. (1983), Gene 26:205–221; Yelton et al. (1984), Proc.Natl. Acad. Sci. USA 81:1470–1474) and A. niger (Kelly and Hynes (1985),EMBO J. 4:475–479).

Suitable host cells for the expression of glycosylated antibody arederived from multicellular organisms. Such host cells are capable ofcomplex processing and glycosylation activities. In principle, anyhigher eukaryotic cell culture is workable, whether from vertebrate orinvertebrate culture. Examples of invertebrate cells include plant andinsect cells. Numerous baculoviral strains and variants andcorresponding permissive insect host cells from hosts such as Spodopterafrugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus(mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori havebeen identified. See, e.g., Luckow et al. (1988), Bio/Technology6:47–55; Miller et al., Genetic Engineering, Setlow et al. (1986), eds.,Vol. 8 (Plenum Publishing), pp. 277–279; and Maeda et al. (1985), Nature315:592–594. A variety of viral strains for transfection are publiclyavailable, e.g., the L-1 variant of Autographa californica NPV and theBm-5 strain of Bombyx mori NPV, and such viruses may be used as thevirus herein according to the present invention, particularly fortransfection of Spodoptera frugiperda cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato,and tobacco can be utilized as hosts. Typically, plant cells aretransfected by incubation with certain strains of the bacteriumAgrobacterium tumefaciens, which has been previously manipulated tocontain the antibody DNA. During incubation of the plant cell culturewith A. tumefaciens, the DNA encoding the antibody is transferred to theplant cell host such that it is transfected, and will, under appropriateconditions, express the antibody DNA. In addition, regulatory and signalsequences compatible with plant cells are available, such as thenopaline synthase promoter and polyadenylation signal sequences.Depicker et al. (1982), J. Mol. Appl. Gen. 1:561. In addition, DNAsegments isolated from the upstream region of the T-DNA 780 gene arecapable of activating or increasing transcription levels ofplant-expressible genes in recombinant DNA-containing plant tissue. EP321,196 published 21 Jun. 1989.

However, interest has been greatest in vertebrate cells, and propagationof vertebrate cells in culture (tissue culture) has become a routineprocedure in recent years (Tissue Culture (1973), Academic Press, Kruseand Patterson, editors). Examples of useful mammalian host cell linesare monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);human embryonic kidney line (293 or 293 cells subcloned for growth insuspension culture, Graham et al. (1977), J. Gen Virol. 36:59); babyhamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovarycells/−DHFR (CHO, Urlaub and Chasin (1980), Proc. Natl. Acad. Sci. USA77:4216); mouse sertoli cells (TM4, Mather (1980), Biol. Reprod.23:243–251); monkey kidney cells (CV1 ATCC CCL 70); African green monkeykidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells(HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo ratliver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT060562, ATCC CCL51); TR1 cells (Mather et al. (1982), Annals N.Y. Acad.Sci. 383:44–68); MRC 5 cells; FS4 cells; and a human hepatoma line (HepG2).

Host cells are transfected and preferably transformed with theabove-described expression or cloning vectors of this invention andcultured in conventional nutrient media modified as appropriate forinducing promoters, selecting transformants, or amplifying the genesencoding the desired sequences.

Transfection refers to the taking up of an expression vector by a hostcell whether or not any coding sequences are in fact expressed. Numerousmethods of transfection are known to the ordinarily skilled artisan, forexample, CaPO₄ and electroporation. Successful transfection is generallyrecognized when any indication of the operation of this vector occurswithin the host cell.

Transformation means introducing DNA into an organism so that the DNA isreplicable, either as an extrachromosomal element or by chromosomalintegrant. Depending on the host cell used, transformation is done usingstandard techniques appropriate to such cells. The calcium treatmentemploying calcium chloride, as described in section 1.82 of Sambrook etal., supra, is generally used for prokaryotes or other cells thatcontain substantial cell-wall barriers. Infection with Agrobacteriumtumefaciens is used for transformation of certain plant cells, asdescribed by Shaw et al. (1983), Gene 23:315, and WO 89/05859 published29 Jun. 1989. In addition, plants may be transfected using ultrasoundtreatment as described in WO 91/00358 published 10 Jan. 1991. Formammalian cells without such cell walls, the calcium phosphateprecipitation method of Graham and van der Eb (1978), Virology52:456–457, is preferred. General aspects of mammalian cell host systemtransformations have been described by Axel in U.S. Pat. No. 4,399,216issued 16 Aug. 1983. Transformations into yeast are typically carriedout according to the method of Van Solingen et al. (1977), J. Bact.130:946, and Hsiao et al. (1979), Proc. Natl. Acad. Sci. (USA) 76:3829.However, other methods for introducing DNA into cells such as by nuclearinjection, electroporation, or protoplast fusion may also be used.

Prokaryotic cells used to produce the antibody polypeptide of thisinvention are cultured in suitable media as described generally inSambrook et al., supra.

The mammalian host cells used to produce the antibody of this inventionmay be cultured in a variety of media. Commercially available media suchas Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640(Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) aresuitable for culturing the host cells. In addition, any of the mediadescribed in Ham and Wallace (1979), Meth. Enz. 58:44, Barnes and Sato(1980), Anal. Biochem. 102:255, U.S. Pat. Nos. 4,767,704; 4,657,866;4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; or U.S. Pat. Re.30,985; the disclosures of all of which are incorporated herein byreference, may be used as culture media for the host cells. Any of thesemedia may be supplemented as necessary with hormones and/or other growthfactors (such as insulin, transferrin, or epidermal growth factor),salts (such as sodium chloride, calcium, magnesium, and phosphate),buffers (such as HEPES), nucleosides (such as adenosine and thymidine),antibiotics (such as Gentamycin™ drug), trace elements (defined asinorganic compounds usually present at final concentrations in themicromolar range), and glucose or an equivalent energy source. Any othernecessary supplements may also be included at appropriate concentrationsthat would be known to those skilled in the art. The culture conditions,such as temperature, pH, and the like, are those previously used withthe host cell selected for expression, and will be apparent to theordinarily skilled artisan.

The host cells referred to in this disclosure encompass cells in invitro culture as well as cells that are within a host animal.

Gene amplification and/or expression may be measured in a sampledirectly, for example, by conventional Southern blotting, northernblotting to quantitate the transcription of mRNA (Thomas (1980), Proc.Natl. Acad. Sci. USA 77:5201–5205), dot blotting (DNA analysis), or insitu hybridization, using an appropriately labeled probe, based on thesequences provided herein. Various labels may be employed, most commonlyradioisotopes, particularly ³²P. However, other techniques may also beemployed, such as using biotin-modified nucleotides for introductioninto a polynucleotide. The biotin then serves as the site for binding toavidin or antibodies, which may be labeled with a wide variety oflabels, such as radionuclides, fluorescers, enzymes, or the like.Alternatively, antibodies may be employed that can recognize specificduplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybridduplexes or DNA-protein duplexes. The antibodies in turn may be labeledand the assay may be carried out where the duplex is bound to a surface,so that upon the formation of duplex on the surface, the presence ofantibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunologicalmethods, such as immunohistochemical staining of tissue sections andassay of cell culture or body fluids, to quantitate directly theexpression of gene product. With immunohistochemical stainingtechniques, a cell sample is prepared, typically by dehydration andfixation, followed by reaction with labeled antibodies specific for thegene product coupled, where the labels are usually visually detectable,such as enzymatic labels, fluorescent labels, luminescent labels, andthe like. A particularly sensitive staining technique suitable for usein the present invention is described by Hsu et al. (1980), Am. J. Clin.Path. 75:734–738.

Antibody preferably is recovered from the culture medium as a secretedpolypeptide, although it also may be recovered from host cell lysateswhen directly expressed without a secretory signal.

When the antibody is expressed in a recombinant cell other than one ofhuman origin, the antibody is completely free of proteins orpolypeptides of human origin. However, it is still usually necessary topurify the antibody from other recombinant cell proteins or polypeptidesto obtain preparations that are substantially homogeneous as to theligand per se. As a first step, the culture medium or lysate iscentrifuged to remove particulate cell debris. The membrane and solubleprotein fractions are then separated. Alternatively, a commerciallyavailable protein concentration filter (e.g., AMICON or MilliporePELLICON ultrafiltration units) may be used. The antibody may then bepurified from the soluble protein fraction. The antibody thereafter ispurified from contaminant soluble proteins and polypeptides by saltingout and exchange or chromatographic procedures employing-various gelmatrices. These matrices include; acrylamide, agarose, dextran,cellulose and others common to protein purification. Exemplarychromatography procedures suitable for protein purification includeimmunoaffinity, FIX Gla domain affinity (e.g., -IgG or protein ASEPHAROSE), hydrophobic interaction chromatography (HIC) (e.g., ether,butyl, or phenyl Toyopearl), lectin chromatography (e.g., ConA-SEPHAROSE, lentil-lectin-SEPHAROSE), size exclusion (e.g., SEPHADEXG-75), cation- and anion-exchange columns (e.g., DEAE or carboxymethyl-and sulfopropyl-cellulose), and reverse-phase high performance liquidchromatography (RP-HPLC) (see e.g., Urdal et al. (1984), J. Chromatog.296:171, where two sequential RP-HPLC steps are used to purifyrecombinant human IL-2). Other purification steps optionally include;ethanol precipitation; ammonium sulfate precipitation; chromatofocusing;preparative SDS-PAGE, and the like.

Antibody variants in which residues have been deleted, inserted, orsubstituted are recovered in the same fashion, taking account of anysubstantial changes in properties occasioned by the variation. Forexample, preparation of an antibody fusion with another protein orpolypeptide, e.g., a bacterial or viral antigen, facilitatespurification; an immunoaffinity column containing antibody to theantigen can be used to adsorb the fusion polypeptide. Immunoaffinitycolumns such as a rabbit polyclonal anti-antibody column can be employedto absorb the antibody variant by binding it to at least one remainingimmune epitope. Alternatively, the antibody may be purified by affinitychromatography using a purified FIX Gla domain-IgG coupled to a(preferably) immobilized resin such as AFFI-Gel 10 (Bio-Rad, Richmond,Calif.) or the like, by means well known in the art. A proteaseinhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may beuseful to inhibit proteolytic degradation during purification, andantibiotics may be included to prevent the growth of adventitiouscontaminants. One skilled in the art will appreciate that purificationmethods suitable for the native antibody may require modification toaccount for changes in the character of the antibody or its variantsupon expression in recombinant cell culture.

Utility

The antibodies disclosed herein are useful for in vitro diagnosticassays for inhibiting the activation of FIX to FIXa by FXIa or byTF-FVIIa and in inhibiting coagulation in a FIXa dependent assay.

The compositions of this invention may be used in the treatment andprevention of FIXa mediated diseases or disorders including but are notlimited to the prevention of arterial re-thrombosis in combination withthrombolytic therapy. It has been suggested that the FIX plays asignificant role in a variety of clinical states including deep venousthrombosis, arterial thrombosis, stroke, DIC, septic shock,cardiopulmonary bypass surgery, adult respiratory distress syndrome,hereditary angioedema as well as tumor growth and metastasis. Inhibitorsof FIX may therefore play important roles in the regulation ofinflammatory and/or thrombotic disorders.

Thus the present invention encompasses a method for preventing aFIX/FIXa mediated event in a human comprising administering to a patientin need thereof a therapeutically effective amount of the antibodycomposition of the present invention. A therapeutically effective amountof the antibody molecule of the present invention is predetermined toachieve the desired effect. The amount to be employed therapeuticallywill vary depending upon therapeutic objectives, the routes ofadministration and the condition being treated. Accordingly, the dosagesto be administered are sufficient to bind to available FIX/FIXa and forman inactive complex leading to decreased coagulation in the subjectbeing treated.

The therapeutic effectiveness is measured by an improvement in one ormore symptoms associated with the FIXa dependent coagulation. Suchtherapeutically effective dosages can be determined by the skilledartisan and will vary depending upon the age condition, sex andcondition of the subject being treated. Suitable dosage ranges forsystemic administration are typically between about 1 μg/kg to up to 100mg/kg or more and depend upon the route of administration. According tothe present invention a preferred therapeutic dosage is between about 1μg/kg body weight and about 5 mg/kg body weight. For example, suitableregimens include intravenous injection or infusion sufficient tomaintain concentration in the blood in the ranges specified for thetherapy contemplated.

Pharmaceutical compositions which comprise the antibodies or antibodyfragments of the invention may be administered in any suitable manner,including parental, topical, oral, or local (such as aerosol ortransdermal) or any combination thereof. Suitable regimens also includean initial administration by intravenous bolus injection followed byrepeated doses at one or more intervals.

Where the composition of the invention is being administered incombination with a thrombolytic agent, for example, for the preventionof reformation of an occluding thrombus in the course of thrombolytictherapy, a therapeutically effective dosage of the thrombolytic isbetween about 80 and 100% of the conventional dosage range. Theconventional dosage range of a thrombolytic agent is the daily dosageused in therapy and is readily available to the treating physician.(Physicians Desk Reference (1994), 50th Edition, Edward R. Barnhart,publisher). The typical dosage range will depend upon the thrombolyticbeing employed and include for tissue plasminogen activator (t-PA), 0.5to about 5 mg/kg body weight; streptokinase, 140,000 to 2,500,0000 unitsper patient; urokinase, 500,000 to 6,250,00 units per patient; andanisolated streptokinase plasminogen activator complex (ASPAC), 0.1 toabout 10 units/kg body weight.

The term combination as used herein includes a single dosage formcontaining at least the molecule of the present invention and at leastone thrombolytic agent. The term is also meant to include multipledosage forms wherein the molecule of the present invention isadministered separately but concurrently by two separate administration,such as in sequential administration. These combinations andcompositions work to dissolve or prevent the formation of an occludingthrombus resulting in dissolution of the occluding thrombus.

When used for in vivo administration, the antibody formulation must besterile. This is readily accomplished by filtration through sterilefiltration membranes, prior to or following lyophilization andreconstitution. The antibody ordinarily will be stored in lyophilizedform or in solution.

Therapeutic antibody compositions generally are placed into a containerhaving a sterile access port, for example, an intravenous solution bagor vial having a stopper pierceable by a hypodermic injection needle.

The route of antibody administration is in accord with known methods,e.g., injection or infusion by intravenous, intraperitoneal,intracerebral, intramuscular, intraocular, intraarterial, intrathecal,inhalation or intralesional routes, or by sustained release systems asnoted below. The antibody is preferably administered continuously byinfusion or by bolus injection.

The antibodies of the invention may be prepared in a mixture with apharmaceutically acceptable carrier. This therapeutic composition can beadministered intravenously or through the nose or lung, preferably as aliquid or powder aerosol (lyophilized). The composition may also beadministered parenterally or subcutaneously as desired. Whenadministered systematically, the therapeutic composition should besterile, pyrogen-free and in a parenterally acceptable solution havingdue regard for pH, isotonicity, and stability. These conditions areknown to those skilled in the art. Briefly, dosage formulations of thecompounds of the present invention are prepared for storage oradministration by mixing the compound having the desired degree ofpurity with physiologically acceptable carriers, excipients, orstabilizers. Such materials are non-toxic to the recipients at thedosages and concentrations employed, and include buffers such as TRISHCl, phosphate, citrate, acetate and other organic acid salts;antioxidants such as ascorbic acid; low molecular weight (less thanabout ten residues) peptides such as polyarginine, proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidinone; amino acids such as glycine, glutamic acid,aspartic acid, or arginine; monosaccharides, disaccharides, and othercarbohydrates including cellulose or its derivatives, glucose, mannose,or dextrins; chelating agents such as EDTA; sugar alcohols such asmannitol or sorbitol; counterions such as sodium and/or nonionicsurfactants such as TWEEN®, Pluronics or polyethyleneglycol.

Sterile compositions for injection can be formulated according toconventional pharmaceutical practice. For example, dissolution orsuspension of the active compound in a vehicle such as water ornaturally occurring vegetable oil like sesame, peanut, or cottonseed oilor a synthetic fatty vehicle like ethyl oleate or the like may bedesired. Buffers, preservatives, antioxidants and the like can beincorporated according to accepted pharmaceutical practice.

Suitable examples of sustained-release preparations includesemipermeable matrices of solid hydrophobic polymers containing thepolypeptide, which matrices are in the form of shaped articles, e.g.,films, or microcapsules. Examples of sustained-release matrices includepolyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) asdescribed by Langer et al. (1981), J. Biomed. Mater. Res. 15:167–277,and Langer (1982), Chem. Tech. 12:98–105, or poly(vinylalcohol)),polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers ofL-glutamic acid and gamma ethyl-L-glutamate (Sidman et al. (1983),Biopolymers 22:547–556), non-degradable ethylene-vinyl acetate (Langeret al., supra), degradable lactic acid-glycolic acid copolymers such asthe LUPRON Depot™ (injectable microspheres composed of lacticacid-glycolic acid copolymer and leuprolide acetate), andpoly-D-(−)-3-hydroxybutyric acid (EP 133,988).

While polymers such as ethylene-vinyl acetate and lactic acid-glycolicacid enable release of molecules for over 100 days, certain hydrogelsrelease proteins for shorter time periods. When encapsulated proteinsremain in the body for a long time, they may denature or aggregate as aresult of exposure to moisture at 37° C., resulting in a loss ofbiological activity and possible changes in immunogenicity. Rationalstrategies can be devised for protein stabilization depending on themechanism involved. For example, if the aggregation mechanism isdiscovered to be intermolecular S—S bond formation through disulfideinterchange, stabilization may be achieved by modifying sulfhydrylresidues, lyophilizing from acidic solutions, controlling moisturecontent, using appropriate additives, and developing specific polymermatrix compositions.

The following examples are offered by way of illustration and not by wayof limitation. The disclosures of all citations in the specification areexpressly incorporated herein by reference.

EXAMPLES Example I

Reagents. FIX and FXIa was from Haematologic Technologies Inc., (EssexJct., VT). FX was from Enzyme Research Laboratories Inc. (South Bend,Ind.), dioleoyl 1,2-diacyl-sn-glycero-3-(phospho-L-serine) (PS) andoleoyl 1,2-diacyl-sn-glycero-3-phosphocholine (PC) from Avanti PolarLipids Inc. (Alabaster, Ala.). FIXa chromogenic substrate #299 was fromAmerican Diagnostica (Greenwich, Conn.). Actin FS and Innovin wereobtained from Dade International Inc. (Miami, Fla.). SEPHAROSE™ resinsand columns were from Amersham Pharmacia Biotech (Piscataway, N.J.).DiaEthyleneglycol (analytical grade) and FeCl₃ (reagent grade) were fromMallinckrodt Inc. (Paris, Ky.). Fatty acid-free BSA was from Calbiochem(La Jolla, Calif.). Sodium heparin for injection was from Elkins SinnInc. (Cherry Hill, N.J.). Sterile saline for injection was purchasedfrom Baxter Healthcare Corp. (Deerfield, Ill.). Purified TF (1-243) fromE. coli and recombinant F.VIIa were kindly provided by Robert F. Kelley(Genentech, Inc.).

Methods

Synthesis and biotinylation of Gla peptide: Gla peptide synthesis wasperformed on an ABI431 Peptide Synthesizer using standard Fmoc chemistryprotocols on a 0.25 mmol scale. Couplings were carried out with HBTU[2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexaflourophosphate], HOBT (N-hydroxybenzotriazole), and DIPEA(diisopropylethylamine) for 1 hour. Fmoc amino acid side chainprotecting groups were as follows: Tyr(tBut), Thr(tBut), Ser(tBut),Lys(Boc), Arg(pbf), Asn(trt), Gln(trt), Gla(OtBut)2, Cys(acm) andTrp(Boc). Oxidation was carried out with the peptide still on the resinby stirring the resin with 10 equivalents of iodine in DMF at 4° C. for1 hour. The peptide was cleaved using 70:30:0.1TFA:dichloromethane:triisopropylsilane for 3 hours at room temperature,triturated with ether, extracted off the resin with 30 mM NH4OH andlyophilized. The identity of the material was confirmed by electrospraymass spectrometry, peptide sequencing and amino acid analysis.Fmoc-L-Gla(OtBut)2 was obtained from Peninsula Labs (Belmont Calif.) andFmoc-Lys(alloc) from Perseptive Biosystems (Framingham Mass.). Thecatalyst Pd(0) and Biotin-NHS were purchased from Fluka (RonkonkomaN.Y.) and Sigma (St Louis Mo.), respectively.

Biotinylated Gla peptide synthesis was modified from the above procedureas follows. The peptide synthesis was carried out using Fmoc-Lys (alloc)in position 40 and the final Fmoc group on the N-terminus of the peptidewas not removed. Removal of the alloc (allyloxycarbonyl) group was donewith a palladium catalyst using a 0.1 M solution oftetrakistriphenylphosphine palladium(0) with 5% acetic acid and 2.5%N-methylmorpholine in chloroform for 3 hours. Biotin-NHS(N-hydroxysuccinimidobiotin) was coupled to the side chain of Lysine(40)with DIPEA overnight in DMF/DCM. Then the final Fmoc group was removedwith 20% piperidine/DMF and the peptide was oxidized on the resin,cleaved off the resin and extracted off the resin as described in theprevious paragraph.

Results

The amino acid sequence of the synthesized Gla peptide is shown in FIG.1 (human).

Example 2

Methods

Biopanning procedure—A large library of 10¹⁰ scFv (Cambridge AntibodyTechnology, Cambridgeshire, UK) (Vaughan et al. (1996) NatureBiotechnology 14:309–314) was panned through two rounds of enrichmentagainst biotinylated peptide. Affinity-driven selection (Hawkins et al.,(1992) J. Mol. Biol. 226:889–896) was performed by decreasing the amountof antigen at each subsequent round of panning (100 nM and 10 nM, forrounds 1 and 2, respectively). To ensure proper conformation of the Glapeptide, calcium chloride (2 mM) was added to all solutions, unlessindicated otherwise, during the panning procedure and all subsequentassays. For each selection, approximately 10¹² titered units of phage,blocked in 1 ml of TBS containing 3% skimmed milk, 0.1% TWEEN® and 2 mMCaCl₂ (MTBST/Ca), were incubated for 1 hr at room temperature (RT) withthe biotinylated peptide. Streptavidin-conjugated beads (DYNABEADS®,Dynal, Oslo Norway) blocked in MTBS, were added to thephage-biotinylated antigen mixture for 15 min. at RT. A volume of 300 μlof DYNABEADS® was used for round 1, and was decreased to 100 μl at round2. The DYNABEADS® were washed three times with each of the followingsolutions TBST/Ca, MTBST/Ca, MTBS/Ca, and TBS/Ca, using a DYNAL MPC®(Magnetic Particle Concentrator). Bound phage were eluted step-wise with4M MgCl₂, 1 mM Tetra-ethylamine (TEA), and 100 mM HCl. Each elution wasperformed at RT for 5 min, and eluted fractions were neutralized with 50mM Tris-HCl, pH 7.5. Phage recovered after each round of panning werepropagated in the bacterial suppressor strain TG1.

Results

Isolation and characterization of scFvs to human FIX—In an attempt toisolate antibodies specific to human FIX with potential anti-thromboticactivity, a phage-displayed library of human scFv antibodies with apeptide corresponding to the Gla domain of human FIX was screened. Sincethe binding of Ca⁺⁺ to FIX Gla domain was shown to induce conformationalchanges important for interaction with phospholipids and cell surfaces,all panning selection steps were performed in the presence of 2 mMCaCl₂. Two rounds of panning were done in solution with 100 nM and 10 nMof biotinylated peptide, respectively. After the second round ofpanning, 96 out of 800 clones screened (12%) were selected on theirability to bind to the FIX Gla peptide specifically by phage ELISA(Griffiths et al. (1993), EMBO J. 12:725–734).

Example 3

Methods

Clone characterization—MAXISORP™ Elisa plates (Nunc) were coatedovernight at 4° C. with Gla peptide (5 μg/ml) in HEPES buffered saline(HBS). Plates were blocked with HBS buffer containing 0.1% TWEEN® and 3%milk powder. Phage culture supernatants (50 μl) were directly applied tothe plates. Horseradish peroxidase (HRP)-conjugated anti-M13 (Pharmacia,Uppsala, Sweden) was then added. DNA purified from selected clones wascharacterized by BstNI digestion and sequencing (ABI377, Perkin Elmer,Foster City, Calif.).

ScFv protein ELISA—ELISA plates were coated with either the anti-c mycantibody 9E10 in carbonate buffer (format I), FIX or FIX-relatedfactors, in HBS with 2 mM CaCl₂ (HBSCa) (format II). Plates were blockedwith HBSCa containing 0.1% TWEEN® (HBST/Ca). ScFv were added at aconcentration of 5 μg/ml. In format I, biotinylated FIX (1 μg) wasapplied to the plates followed by Streptavidin-HRP. In format II,detection of scFv was performed using 9E10 anti-c myc mAb and anHRP-conjugated goat anti-mouse Fc-specific mAb (Zymed, South SanFrancisco, Calif.). All reagent dilutions were prepared in blockingbuffer HBST/Ca and plates were washed with HBS/Ca containing 0.05%TWEEN®.

Results

To further assess germline diversity of the selected clones, DNA waspurified from individual clones and subjected to BstNI fingerprinting(Clackson et al, (1991) Nature 352:624–628). The 96 clones wereclassified into 24 distinct fingerprint families. ScFvs were expressedas epitope-tagged proteins containing a c-myc tag sequence recognized bymonoclonal antibody 9E10 (Griffiths et al. (1993), EMBO J. 12:725–734)and a polyhistidine tag (his6) and were purified over Ni-NTA withimidazole elution as recommended by the manufacturer (Qiagen,Chatsworth, Calif.). One clone from each fingerprint family was selectedfor scFv expression. Purified scfv were then tested for their reactivityto Gla peptide and full length FIX by ELISA. Out of the 24 clonestested, six clones (10C12, 11C5, 11G9, 13D1, 13H6, and 14H9) were shownto crossreact to various extent with both the Gla peptide and fulllength FIX by ELISA (FIG. 4), all others reacted with Gla peptide only.Clones 10C12, 13D1 and 13H6 exhibited stronger binding to FIX thanclones 11G9, 11C5, and 14H9.

These six clones were further characterized by DNA sequencing to analyzesegment usage (FIG. 2). Four clones (10C12, 11C5, 11G9, and 13D1)displayed the same light chain (Vλ1) with identical CDR regions. Clones13H6 and 14H9 light chains were unique and different from the others,with no homology found in the CDR regions. Sequencing of the heavychains revealed strong homology between clones 10C12 and 13D1 withdifferences at only 3 residues, one located in CDR₂ and two in the framework regions. Clone 11C5 heavy chain had almost identical CDR1 and CDR2as 10C12 and 13D1 but a different CDR₃ region. Clones 13H6 and 14H9heavy chains showed little homology to the other clones. These resultsshow that 10C12, 11C5, 11G9, and 13D1 are closely related, the moststriking difference residing in clone 11C5 heavy chain CDR₃ region. Theoverall homology suggests that these antibodies bind an identicalepitope within the FIX-Gla domain. In the presence of Ca++ and Mg++, theFIX Gla domain adopts different conformations which expose distinctantibody epitopes. The antibodies 10C12, 13D1, 11C5 and 13H6 whichdisplay high homology in their CDRs (except for 13H6) exclusively boundto the Ca++induced conformation of the Gla domain, consistent with theview that they recognize a common epitope. In contrast, clones 13H6 and14H9 both have unique heavy and light chains. Clone 14H9 appears to havesignificantly more charged residues in the CDR domains, especially inCDR₃.

Four of the six antibodies were chosen to be reformatted as F(ab′)₂molecules, based on strong FIXa inhibiting activity (10C12, 13D1, and13H6) and DNA germline diversity (14H9).

Binding specificity of scFvs and F(ab′)₂ to various blood coagulationfactors—There is a high degree of homology between Gla domains ofdifferent blood coagulation factors (FVII, FIX, FX, prothrombin, andprotein C) (see FIG. 1B). To determine the specificity of the antibodiesselected for binding to FIX Gla domain, ELISA experiments were performedby coating various factors (FIX, FVII, FX, prothrombin and protein C)onto plates and incubating with scFvs (FIG. 6A) or F(ab′)₂ (FIG. 6B) ata concentration of 5 μg/ml (0.02 μg/ml for F(ab′)₂). Results showed thatboth scFv and F(ab′)₂ from clones 10C12, 13D1 and 13H6 reacted with FIXonly while 14H9 recognized all factors tested. Moreover, binding of scFvfrom clones 10C12, 13D1 and 13H6 to FIX was not reduced when scFvs werepreincubated with FIX deficient serum, ruling out any interaction ofthese clones with factors, other than FIX, present in the serum. Incontrast, binding of scFv from clone 14H9 was greatly diminished afterincubation of scFv with the same serum. These results demonstrated thatthe epitope recognized by clone 14H9 is unique and different from thesequence seen by the other 3 antibodies.

Calcium and magnesium dependence of anti-FIX F(ab′)₂ binding to FIX—Theselection of scFv antibodies described in this study was performed inpresence of Ca⁺⁺ ions. FIX has been shown to undergo two metal-dependentconformational transitions, one metal-dependent but cationnon-selective, the second one metal-selective for Ca⁺⁺ or Sr⁺⁺. To testthe influence of metal ions on the binding of the anti-FIX antibodies,ELISA experiments were performed with either Ca⁺⁺, Mg⁺⁺, or EDTA (whichchelates Ca⁺⁺ ions) added to all buffers. Results indicated that clones10C12, 13D1 and 13H6 recognized FIX only in the presence of Ca⁺⁺, andthe binding was partially or completely inhibited in presence of 2 mMEDTA. In contrast, clone 14H9 did bind to FIX in presence of either Mg⁺⁺or Ca⁺⁺. No inhibition was observed in presence of EDTA whichdemonstrated that Ca⁺⁺ ions were not necessary for the binding to occur.

Example 4

Methods

BIAcore evaluation of anti-FIX F(ab′) 2 affinities—The antigen-bindingaffinities of several (Fab′)₂ “leucine-zipper” fragments were calculated(Löfås & Johnsson (1990), J. Chem. Soc. Commun. 21:1526–1528) fromassociation and dissociation rate constants measured using aBIAcore-2000™ surface plasmon resonance system (Pharmacia Biosensor). Abiosensor chip was activated usingN-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) andN-hydroxysuccinimide (NHS) according to the supplier's (BIAcore, Inc.,Piscataway, N.J.) instructions. Factor IX, and Factor X as a negativecontrol, were diluted approximately 30 μg/mL in 10 mM sodium acetatebuffer (pH 4.5). Aliquots were injected to achieve approximately 519response units (RU) of coupled FIX, and 2330 RU or 13,590 RU of coupledFX. Finally, 1M ethanolamine was injected as a blocking agent.

For kinetics measurements, 2-fold serial dilutions (10 μL) of antibodywere injected in running buffer (0.05% Tween-20, 150 mM NaCl, 2 mMCaCl₂, 10 mM Hepes pH 7.4) at 25° C. using a flow rate of 10 μL/min.Regeneration was achieved with 4.5 M MgCl₂, followed by wash solution(50 mM EDTA, 150 mM NaCl, 0.05% TWEEN-20®). Equilibrium dissociationconstants, Kd's, from SPR measurements were calculated ask_(off)/k_(on). Dissociation data were fit to a simple 1:1 Langmuirbinding model. Pseudo-first order rate constant (ks) were calculated foreach association curve, and plotted as a function of proteinconcentration to obtain k_(on) +/−s.e. (standard error of fit). Theresulting errors e[K] in calculated K_(d)'s were calculated as follows:e[K]=[(k _(on))⁻²(s _(off))²+(k _(off))²(k _(on))⁴(s _(on))²]^(1/2)where s_(off) and s_(on) are the standard errors in k_(on) and k_(off),respectively.Results

Affinity measurement of anti-FIX F(ab′)₂ binding to FIX—In SPR bindingexperiments, F(ab′)₂-zipper forms of 10C12, 13D1, and 13H6 showedspecific binding to FIX (versus F.X, or a blank flow cell). For theseexperiments, a low density (519 RU) of immobilized antigen (FIX) wasused. Although the bivalent form of the antibodies could have resultedin avidity effects in binding to antigen, the binding kinetics observedwere consistent with simple 1:1 models of association and dissociation.All three antibodies had similar dissociation rate constants (k_(off)),corresponding to dissociation half-lives of about 50–70 minutes (FIG.3). The association rate (k_(on)) for 13H6, however, was significantlyfaster than 10C12 or 13D1. Consequently the equilibrium dissociationconstant (K_(d)) for 13H6 is lower (K_(d)=0.45 nM) than 10C12 (K_(d)=1.6nM) or 13D1 (2.9 nM).

Example 5

Methods

FIX binding to bovine endothelial cells—Primary bovine aorticendothelial cells were grown as described (Marcum et al. (1986), J.Biol. Chem. 261:7507) for four days. Cells were washed with Hepes buffercontaining 10 mM HEPES pH 7.2, 137 mM NaCl, 4 mM KCl, 11 mM Glucose, 5mg/ml BSA and 2 mM CaCl₂. Cells were then incubated at 4° C. for 2 hourswith biotinylated FIX, and/or biotinylated FIX preincubated for 1 hourwith various amounts of cold FIX, scFv or F(ab′)₂ proteins. Plates werewashed and a Streptavidin-HRP conjugate was added for 0.1 hour at RT,followed by TMB/H₂O₂ substrate. Plates were analyzed on a plate readerat 620 nm.

Platelet-dependent coagulation assay Microtiter plates (Linbro #76-232-05) were coated with 4 μg/ml of human collagen III (GibcoBRL#12167-011) in PBS, 1 mM CaCl₂, 1 mM Mg Cl₂ overnight at 4° C. Afterwashing with PBS the plates were further incubated with Tyrode's BSA, 2mM CaCl₂ for 60 min. at 37° C. before use.

Washed platelets were prepared from human citrated whole blood asdescribed (Dennis et al. (1989), Proc. Natl. Acad. Sci. USA87:2471–2475). The washed platelets were adjusted to a concentration ofapproximately 6×10⁸ platelets/ml in Tyrode's BSA and allowed to rest for120 min. at 37° C. After adding 1 mM CaCl₂ and 1 mM MgCl₂, the plateletswere activated with ADP (10 μM final conc.). 60 μl of plateletsuspension was added per well, the plate centrifuged at 60×g for 5 min.and then the platelets were allowed to firmly adhere to thecollagen-coated wells for 60 min at room temperature. The nonadherentplatelets were gently decanted and the plate washed twice with PBScontaining 1 mM CaCl₂ and 1 mM Mg Cl₂. The collagen-adherent plateletlayer was then incubated for 10 min with the antibodies in Tyrode'sBSA-2 mM CaCl₂ (40 μl/well). 60 μl of human citrated plasma (plasma poolfrom Peninsula Blood Bank) recalcified with CaCl₂ (to 11 mM final conc.)was added to each well. Coagulation was quantified by monitoring theincrease in optical density at 405 nm on a kinetic microplate reader(SLT Lab Instruments, model EAR 340AT).

Results

Potent inhibitory effect of scFvs on FIX binding to endothelial cellsand on platelet-dependent coagulation—Since the Gla domain of FIX isknown to be required for the interaction of FIX with phospholipid andcell surfaces (Ryan et al. (1989), J. Biol. Chem. 264:20283–20287;Toomey et al. (1992), Biochemistry 31:1806–1808; Cheung et al. (1992),J. Biol. Chem. 267:20529–20531; Ahmad et al. (1994), Biochem.33:12048–12055), scFv generated against FIX Gla domain were furthertested for their ability to block the binding of FIX to endothelialcells. In a competition assay using bovine aortic endothelial cells,binding of biotinylated FIX to the cells was measured in absence orpresence of scFvs from either clones 10C12, 11C5, 11G9, 13D1, 13H6,14H9, 6E11 or unlabeled FIX. The results of this experiment are shown inFIG. 5A. ScFv from clones 10C12, 13D1, 13H6 and 11G9 exhibited the mostpotent inhibitory effect on FIX binding, similar to unlabeled FIX (IC50equivalent to 20–50 nM). ScFv from clones 11C5, 6E11 and 14H9 showedmuch weaker inhibition (IC50 >300 nM).

The FIX Gla domain also contains a major determinant for binding toplatelets (Ahmad et al. (1994), supra). A human platelet-dependentplasma coagulation assay was used to assess the potency of the variousscFvs as inhibitors of FIX activity. In this assay, washed humanplatelets were activated and allowed to adhere to collagen, andplatelet-free recalcified human plasma was added. The ongoingcoagulation was monitored as change in optical density up to 90 min.Omission of the platelets or use of FIX-deficient plasma in the presenceof platelets did not lead to any significant change in absorbance overthis time period. These findings indicate that coagulation in this invitro system is dependent on platelets and FIXa activity. As shown inFIG. 5B, scFv from clones 10C12, 11G9, 13H6, and 13D1 completelyinhibited clot formation at a concentration of 500 nM. At thisconcentration, 14H9 had no effect whereas 11C5 showed an intermediateresponse. At a higher concentration (2 μM), both of these scFv werecompletely inhibitory. The potencies of the examined scFvs to interferewith FIXa function in this system rank in the same order as in theendothelial cell binding assay. This may indicate that similarstructural elements of the Gla domain are recognized by endothelialcells and platelets.

Example 6

Methods

Plasma clotting assays—The activated partial thromboplastin time (APTT)and prothrombin time (PT) of plasma from different species were measuredon a ACL 300 (Coulter Corp., Miami, Fla.) using Actin FS (DadeDiagnostics, PR) and human relipidated tissue factor reagent Innovin(Dade International Inc., Miami, Fla.) as coagulation initiators. Forthe rabbit PT, rabbit thromboplastin C Plus (Dade Diagnostics, PR) wasused. Innovin was a potent initiator of clotting across all speciesexamined here, in agreement with the findings of Janson et al. (1984)Haemostasis 14:440–444 that human relipidated tissue factor caneffectively clot plasma from different animal species. The plasmaderived from citrated blood of New Zealand white rabbits, C-57 mice,Sprague-Dawley rats and dogs were prepared by standard procedures andstored at −80° C. Human pooled plasma was obtained from the PeninsulaBlood Bank (Burlingame, Calif.). The anti-FIX antibodies were incubateddiluted 10-fold in citrated plasma and incubated for 10 min beforeclotting was started by adding Actin FS and CaCl₂ (for APTT) or Innovin(for PT). The effect of the antibodies was expressed as x-foldprolongation which is the ratio of clotting times in the presence andabsence (=control) of antibody.

FX activation by the FVIIIa: FIXa complex ion phospholipids—A mixture of0.5 nM Factor IXa, 0.7 U/ml F.VIII, 200 μM phospholipid vesicles(PC:PS=7:3) and 10 mM CaCl₂ in HBSA buffer (0.1 M Hepes, pH 7.5, 0.14 MNaCl, 0.5 mg/ml fatty acid-free BSA) was incubated with α-thrombin (2.8nM) for 1 min at room temperature to activate FVIII. Thrombin activitywas neutralized by addition of 23.3 nM hirudin. The antibodies wereadded to the mixture and incubated for 20 min at RT before 0.8 μM FX wasadded. In this final reaction mixture the concentration of reactantswas: 0.25 nM FIXa, 0.35 U/ml F.VIIIa, 25 μM phospholipids, 100 nM FX and5 mM CaCl₂. At different time points 50 μl aliquots were added to 150 μlof 20 mM EDTA to stop the reaction. To measure the FXa concentration inthe samples, 50 μl of 1.5 mM S-2765 was added to each well and thechange in absorbance monitored on a kinetic microplate reader (MolecularDevices, Menlo Park, Calif.). The rates of FXa generation weredetermined by using linear regression analysis of the FXa concentrationsvs. time.

Results

Selective inhibition of FIX function by 10C12 and 13H₆F(ab′)₂— A numberof different functional assays were employed to investigate whether theobserved specific binding to FIX by 10C12 and 13H6 also translated intoa specific inhibition of FIX/IXa function. Both 13D1, due to itsidentity to 10C12, and 14H9, due to its non-specific binding pattern,were not pursued further. Firstly, we measured the effects of 10C12 and13H6 on the FIX-dependent APTT and the FIX-independent PT in humanplasma. As shown in FIG. 9A, both antibodies specifically prolonged theAPTT but did not change the PT. A control F(ab′)₂ (anti-neurturin)neither prolonged the APTT nor the PT. Secondly, both 10C12 and13H₆F(ab′)₂ strongly interfered with platelet-dependent coagulation,similar to the results obtained with their single chain forms. 10C12 wasmore potent than 13H6 with an IC₅₀ of 59.0±3 nM compared with 173±43 nM(FIG. 7).

Cross-species reactivity of 10C12 F(ab′)₂— The amino acid sequences ofFIX-Gla domains of different animal species are much conserved (FIG.1A), suggesting that an antibody that binds to human FIX-Gla may alsorecognize plasma FIX/IXa of various animals. The potency of 10C12F(ab′)₂ to inhibit the APTT in plasma from different species wastherefore examined. As shown in FIG. 9B, 10C12 F(ab′)₂ most potentlyprolonged the APTT in dog and to a lesser extent than in rat and rabbitplasma. The specificity of the antibody effect towards FIX/IXa wasevidenced by the absence of any effect on the PT in homologous plasma.

The antibodies were evaluated in a FVIIIa:FIXa-mediated FX activationassay using phospholipid vesicles (PCPS) (FIG. 8). Aconcentration-dependent inhibition of FX activation rates was observedwith half-maximal rate inhibitions of 3.5±1.8 nM for 10C12 and 7.3±1.3nM for 13H6. A non-relevant control F(ab′)₂ directed against neurturin(α-NTN) did not affect the activation rate. Moreover, the antibodies hadno effect on the FXa activity to cleave chromogenic substrate S2765which was used in the second stage of the assay to determine theconcentration of newly formed FXa. Therefore, the effect of theantibodies was solely due to interference with intrinsic Xase function.Together these results indicated that both 10C12 and 13H₆F(ab′)₂specifically inhibited FIX/FIXa function in agreement with theirdemonstrated binding specificity in ELISA-type assays.

Example 7

Inhibitory Mechanism of 10C12

Methods

Activation of FIX by FXIa. Antibodies were incubated with FIX in 20 mMhepes, pH7.5, 0.15M NaCl, 5 mM CaCl₂, 0.05% BSA (HBSA buffer) usingmicrotiter tubes (8.8×45 mm, OPS, Petaluma, Calif.). After a 20 minuteincubation period FXIa was added to start the reaction. Theconcentration of FIX and FXIa in this reaction mixture were 400 nM and 1nM, respectively. 100 μl aliquots were taken at 30 sec intervals andquenched in 96-well Costar plates (Corning Inc., Corning, N.Y.)containing 125 μl of 30 mM EDTA buffer-60% (v/v) ethyleneglycol.Ethyleneglycol was included because of its enhancing effect on FIXaamdiolytic activity (Sturzebecher et al., (1997) FEBS lett.,412:295–300; Neuenschwander et al., (1997) Thromb. Haemostatsis 78(Suppl.):428). After adding 25 μl of 5 mM FIX substrate #299, FIXaamidolytic activity was measured at 405 nm on a kinetic microplatereader (Molecular Devices, Menlo Park, Calif.). Inhibition by the testedantibodies was expressed as fractional rates (vi/vo) of FIXa generation.

Activation of FIX by tissue factor:F.VIIa complex. TF(1-243) lacking thecytoplasmic domain (Paborsky et al. (1989), Biochemistry 28:8072;Paborsky et al. (1991), J. Biol. Chem. 266:21911–21916) was relipidatedwith PC/PS (7:3 molar ratio) according to Mimms et al. (1981),Biochemistry 20:833–840. Membrane TF (mTF) was prepared from a humanembryonic kidney cell line (293) expressing full length TF (1-263)(Kelley et al. (1997), supra). The cells were washed in PBS, detachedwith 10 mM EDTA and centrifuged twice (2500 rpm for 10 min). The cellpellet (4–5×10⁷ cells/ml) was resuspended in Tris, pH 7.5 andhomogenized in PBS using a pestle homogenizer, followed bycentrifugation (2500 rpm on a Beckman GSA) for 40 min at 4° C. Theprotein concentration of the cell membrane fraction was determined andthe membranes stored in aliquots at −80° C. until use.

Antibodies were incubated with FIX in HBSA buffer for 20 min inmicrotiter tubes. A complex of relipidated TF (1-243) (20 nM) and FVIIa(5 nM) was pre-formed for at least 10 min before it was added to theFIX/antibody incubation solution. In this reaction mixture theconcentrations of relipidated TF (1-243), FVIIa and FIX were 4 nM, 1 nMand 400 nM, respectively. For experiments with mTF, a complex of mTF(membrane protein conc. of 750 μg/ml) and 5 nM FVIIa was pre-formed.This concentration of mTF gave maximal FVIIa activity and was equal tothat seen with relipidated TF (1-243). The concentration of mTF andFVIIa in the reaction mixture was 150 μg/ml (membrane proteinconcentration) and 1 nM, respectively. 100 μl aliquots of the reactionmixture were taken at 30 sec intervals and quenched in 96-well plates(Costar) containing 125 μl of 30 mM EDTA-buffer-60% (v/v)ethyleneglycol. After adding 25 μl of 5 mM FIX substrate #299, FIXaamidolytic activity was measured at 405 nm on a kinetic microplatereader (Molecular Devices, Menlo Park, Calif.). Inhibition by the testedantibodies was expressed as fractional rates (vi/vo) of FIXa generation.Using standard curves with FIXab, it was determined that, in both theTF:FVIIa and the FXIa assay, less than 15% of zymogen FIX was convertedduring the reaction period.

Results

Inhibitory mechanism of 10C12.

The effects of 10C12 on FIX activation mediated by FXIa and the TF:FVIIacomplex were examined. Recently, Stuerzebecher et al. (1997), Febs lett.412:295–300, and Neuenschwander et al. (1997), Thromb. Haemostasis78(suppl.):428 reported that ethyleneglycol enhanced FIXa amidolyticactivity towards certain types of chromogenic substrates. A FIXactivation assay using ethylenglycol to increase the amidolytic activityof newly generated FIXa was derived. As shown in FIG. 10A, 10C12inhibited conversion of FIX into FIXa by FXIa in aconcentration-dependent manner (IC₅₀28.8±1.7 μg/ml;±SD). A controlantibody, anti-neurturin (NTN), which was also formatted as aleucine-zippered F(ab′)₂, had no effect. Because 10C12 binds to the Gladomain of FIX and FIXa, it was not expected that 10C12 would interferewith the ability of FIXa to cleave small chromogenic substrate used tomeasure the concentration of generated FIXa in the assay. To confirmthis assumption, increasing concentrations of FIXa were incubated with100 μg/ml of 10C12 and assayed with FIXa substrate. 10C12 did not changethe rates of substrate cleavage by FIXa, indicating that 10C12 solelyinhibited FXIa-dependent activation of FIX, and not FIXa amidolyticactivity.

Furthermore, the effects of 10C12 on the extrinsic activation of FIXwere measured by using a complex of relipidated TF(1-243) and FVIIa.10C12 inhibited conversion of FIX with a half-maximal inhibition at34.2±1.6 μg/ml, while a control antibody (NTN) had no effect (FIG. 10B).Then, membrane TF (mTF) was used instead of relipidated TF(1-243). Asfor the assays with relipidated TF(1-243), the concentration of mTF usedwere saturating in respect to FVIIa enzymatic activity. The resultsshowed that inhibition of FIX activation by 10C12 was inhibited in asimilar fashion with an IC₅₀ at a somewhat lower concentration (15.4±0.7μg/ml;±SD) as compared to relipidated TF(1-243) (FIG. 10B). To furtherevaluate the specificity of 10C12 for FIX, interference with thefunction of two other Gla-containing coagulation factors, FVIIa and FXwas examined. The rates of FX (200 nM) activation by the relipidatedTF(1-243):FVIIa (0.2 nM/0.04 nM) complex were measured either afterincubating 10C12 for 20 min with FVIIa or with the substrate FX. 10C12at up to 200 μg/ml did not inhibit FXa generation in either experimentalsetting, confirming the specificity of the 10C12 antibody.

Specific inhibition of FIX-dependent coagulation in guinea pig/ratplasma. Whether the specific inhibition of human FIX function by 10C12was maintained for guinea pig and rat FIX was examined. 10C12 wasincubated with platelet-poor plasma derived from citrated blood of ratand guinea pig, and the effects on APTT and PT were measured. 10C12specifically prolonged the APTT in both guinea pig and rat plasma (FIG.11). Two-fold APTT prolongation was at 65 μg/ml (650 nM) and at 60 μg/ml(600 nM) for guinea pig and rat, respectively. These potencies werealmost identical to that in human plasma where 10C12 gave a 2-fold APTTprolongation at 60 μg/ml. A control antibody (NTN) neither affected theAPTT nor the PT. These data suggested that 10C12 bound and neutralizedFIX/IXa in plasma of guinea pig and rat, yet maintained its specificity,as indicated by the unchanged PT. The observed cross-species reactivityand specificity of 10C12 allowed us to examine the antithromboticactivity in established thrombosis models in guinea pig and rat.

Example 8

Administration of anti-IX/IXa Gla Domain Antibodies Prevents Cyclic FlowVariations in Damaged Carotid Arteries Without Affecting Coagulation orBleeding Parameters.

Methods

Production and purification of leucine-zippered 10C12 F(ab′)₂ antibody.cDNAs encoding the variable heavy and light chain of clone 10C12 wereamplified by PCR and subcloned into an expression vector containing bothhuman heavy (F_(d′)) and light chain (lambda) constant regions (Carteret al. (1992) Bio/Technology 10:163–167) as well as a leucine zippersequence (Kostelny et al. (1992), J. Immunol. 148:1547–1553) added atthe 3′ end of the constant heavy chain sequence. This vector wasexpressed in E. coli K12 strain 33B6 (fhuAphoA-delta-E15delta(argF-lac)169 deoC2 degP41(deltaPstI-kanR)IN(rrnDrrnE)1 ilvG2096), derived from the strain W3110. Cells were grownfor 46 hours in an aerated 60 liter fermentor at 30° C. in a medium thatinitially contained 12 mg/l tetracycline, 12 g/l digested casein, 5 mMglucose, 47 mM (NH4)₂SO₄, 10 mM NaH₂PO₄, 18 mM K₂HPO₄, 4 mM trisodiumcitrate, 12 mM MgSO₄, 250 M FeCl₃, and 40 M each of ZnSO₄, MnSO₂, CuSO₄,CoCl₂, H₃BO₃, and NaMoO₄. The fermentation received an automated feed ofammonia:leucine (35:1 molar ratio) to maintain the pH at 7.0 andglucose, adjusted to the highest rate that would prevent acetateaccumulation. Operating conditions were sufficient to supply oxygen at 3mmol/1-min. Expression was induced by phosphate starvation. Final celldensity was 160 OD₅₅₀. Harvested E. coli cell pellet was stored frozenat −70° C. The frozen pellet was broken into small pieces with a malletand mixed with 5 volumes of 20 mM MES (2-{N-Morpholino}ethane-sulfonicacid)/2 M urea/5 mM EDTA/0.25 M NaCl, pH 5.0 (extraction buffer) usingan ultraturax tissue homogenizer until a uniform suspension wasachieved. The cell suspension was then passed through a homogenizer(Model 15M, Gaulin Corp., Everett, Mass.) to disrupt the cells. Theextract was clarified by adjusting the mixture to pH 3.5 with 6 N HCland centrifuging for 20 minutes at 6000×g. The pH of the supernatant wasreadjusted to 5.0 using NaOH. The supernatant was conditioned forchromatography by dilution with 4 parts 20 mM MES/2 M urea, pH 5.0,filtered through a 0.2 micron filter (Millipore Corp., Bedford, Mass.)and applied to a SP-SEPHAROSE™ fast flow cation exchange resinequilibrated in the dilution buffer. The column was washed extensivelyin the same buffer and then with 20 mM MES, pH 5.0. The column waseluted in two steps using 0.5 M NaCl and 1 M NaCl in 20 mM MES buffer,pH 5.0. The 10C12 leucine-zippered F(ab′)₂ was recovered in the 1 MNaCl/20 mM MES fraction. The SP-SEPHAROSE™ pool was loaded in multiplecycles to a Protein G-SEPHAROSE™ fast flow column. The column wasequilibrated and washed with 20 mM Tris/0.5 M NaCl, pH 7.5. Elution waswith 0.1 M acetic acid/0.15 M NaCl, pH 3.0, and the column wasregenerated after each cycle with 20 mM Tris/2 M guanidine HCl, pH 7.5.The combined protein G pools were concentrated approximately 20-foldusing an Amicon stirred cell system (Amicon Inc., Beverly, Mass.)equipped with a YM30 membrane. The concentrated pool was bufferexchanged using a SEPHADEX™ G25 column run in 20 mM NaPO₄/0.15 M NaCl,pH 7.0. The G25 pool was passed through a Q-SEPHAROSE™ fast flow columnin 20 mM NaPO₄/0.15M NaCl, pH 7.0, for endotoxin removal. The final poolcontained 12.5 EU/mg protein and was passed through a 0.22 micronfilter.

As a control antibody for all experiments, the anti-neurturinleucine-zippered F(ab′)₂ antibody (NTN) was used. This antibody was alsoproduced in E. coli and was purified over a protein G fast flow column.The leucine-zippered control F(ab′)₂ and the leucine-zippered 10C12F(ab′)₂ will be simply referred to as anti-neurturin antibody (NTN) and10C12 antibody. The molecular weight of both antibodies was calculatedas 100,000.

Arterial thrombosis model in the guinea pig. Experiments were performedas described by Carteaux et al. (1995), Circulation 91:1568–1574). GOHImale guinea pigs (350–450 g, BRL, Füllinsdorf, Switzerland) wereanesthetized by i.m. injection of 40 mg/kg ketamine HCl (KETASOL-100®,Gräub AG, Bern, Switzerland) and 5 mg/kg xylazine 2% (ROMPUN®, Bayer AG,Leverkusen, Germany). A catheter pressure transducer (Millar 2FMikro-Tip SPC-320 Millar Instr. Inc. Houston, Tex.) was inserted intothe right femoral artery to measure blood pressure and heart rate. Intothe left femoral artery was placed a catheter (TRICATH IN 22G™, Codan,Espergaerde, DK) for blood sampling. A left jugular vein catheter(TRICATH IN 22G™) was also inserted for drug administration. The rightcarotid artery was dissected free and a 0.8 mm diameter siliconecuff-type Doppler flow probe (type D-20-0.8, Iowa Doppler Products,Iowa) was connected to a 20 MHz pulsed Doppler flowmeter module (System6-Model 202, Triton Technology, Inc. San Diego, Calif.) to monitor theblood flow velocity. Blood pressure (mm Hg), heart rate (beats/min) andcarotid blood flow velocity (Volts) were recorded on a Graphtec Linearrecorder VII (Model WR 3101, Hugo Sachs, March-Hugstetten, Germany).

Guinea pigs received a single bolus of saline, 10C12 or control antibody(NTN) via the left jugular vein catheter and after 15 minutes vasculardamage was initiated. Two millimeter distally to the Doppler flow probe,damage to the subendothelium was induced by pinching a 1-mm segment ofthe dissected carotid artery with a rubber covered forceps during 10 sas previously described (Carteaux et al. (1995), supra; Roux et al.(1994), Haemostasis 71:252–256). After damage, the carotid blood flowvelocity would typically decline to complete occlusion followed byrestoration of flow upon gentle shaking of the damaged area to dislodgethe thrombus. The pattern of cyclic flow variations (CFVs) wereestablished similar to those described by Folts (1991), Circulation83:Supple. IV:3–14) in a dog coronary thrombosis model. If no CFVs wereobserved for 5 minutes, an additional pinch was performed on top of thefirst damage. The same procedure was repeated every 5 minutes till CFVsoccurred. Finally, the number of pinches necessary to produce the CFVswere counted over the 40-minute observation period. It was assumed thatseveral pinches are likely to increase the thrombogenicity of thesubendothelial layer of the carotid artery, thus a thrombosis index wascalculated as the ratio of the number of CFVs to the number of pinches(Carteaux et al. (1995), supra). Under these experimental conditions thecalculated shear rate of the carotid artery was around 1500–2800 s⁻¹(Roux et al. (1994), supra).

Blood was collected prior to inhibitor administration (pre-value) and at60 min following drug administration (post-value) for measurement ofactivated clotting time (ACT), prothrombin time (PT), activated partialthromboplastin time (APTT) and blood cell counts. Nail cuticle bleedingtimes were also measured in these animals at the pre- andpost-experimental periods. Thrombus initiation and sample collectiontimes were based on a pilot pharmacokinetic study in which prolongationof APTT reached a maxima within 15 minutes of IV bolus dosing (5 mg/kg,n=2) and then remained essentially unchanged over the following 2 hours.Sample handling, coagulation assays and bleeding time methods aredescribed below.

Cuticle bleeding time measurements in the guinea pig. The cuticlebleeding method was adapted from dog (Giles et al. (1982), Blood60:727–731) and rabbit (Kelley et al. (1997), Blood 89:3219–3227, Himberet al. (1997), Haemostasis 78:1142–1149) models of coagulation dependentbleeding. A standard cut was made at the apex of the nail cuticle by themean of scissors. Blood was allowed to flow freely by maintaining thepaw in contact with the surface of 38° C. water. Cuticle bleeding timewas determined as the amount of time that blood continued to flow fromthe transected cuticle. This procedure was performed in triplicate forboth pre- and post-dose (60 minutes) determinations. The ratio ofpost-treatment to pre-treatment was calculated by dividing the mean ofthe post-treatment value by the mean of the pre-treatment value.

Results

Antithrombotic and hemostatic effects of 10C12 in guinea pig. Toevaluate 10C12's antithrombotic potential in-vivo, a previouslyestablished guinea pig arterial thrombosis model of cyclic flowvariations (CFVs) was used. In 12 control animals which received saline,the number of CFVs during the 40 min measurement period was 11.2±1(±SEM) and the calculated thrombosis index was 9.3±1.5. Administrationof a control antibody (NTN) gave 13.7±1.8 CFVs and a thrombosis index of12.5±2.11. Neither of these thrombotic nor any of the hemostaticendpoints were significantly different from the saline control.Therefore, saline and NTN control data were pooled for subsequentcomparison to 10C12 treatments. The mean (±SEM) thrombosis index of thepooled controls was 10.4±1.2. As shown in FIG. 12, bolus administrationof increasing concentrations of 10C12 resulted in a dose-dependentreduction of CFVs, reaching a highly significant reduction at 6 μg/kg(p<0.01) and complete inhibition of CFVs at 60 μg/kg. At all testeddoses, including 1000 μg/kg, the blood pressure, heart rate, hematocrit,and blood cell counts remained unchanged (data not shown). Likewise,10C12 did not significantly affect (p>0.05 in Kruskal-Wallis test) theAPTT, ACT or PT up to 1000 μg/kg (Table I). However there was a dosedependent increase in APTT and ACT but not PT which reached statisticalsignificance (p≦0.01) at 1000 μg/kg if a 2-tail t-test was used tocompare individual dose groups against the control.

TABLE I Effects of 10C12 antibody on coagulation parameters in guineapig. Data are mean ± SEM Cuticle APTT PT ACT bleeding time Number ofprolongation prolongation prolongation prolongation Rx animals(post/pre)^(A) (post/pre)^(A) (post/pre)^(A) (post/pre)^(A) Control^(B)18 1.10 ± 0.03 1.09 ± 0.01 0.97 ± 0.02 1.00 ± 0.03 10C12   3 μg/kg 71.15 ± 0.05 1.08 ± 0.01 1.06 ± 0.02 0.90 ± 0.02   6 μg/kg 7 1.07 ± 0.031.08 ± 0.02 0.97 ± 0.03 0.92 ± 0.06  10 μg/kg 6 1.11 ± 0.06 1.06 ± 0.031.04 ± 0.03 1.01 ± 0.09  60 μg/kg 3 1.18 ± 0.10 1.10 ± 0.01 1.01 ± 0.090.78 ± 0.04 1000 μg/kg 3 1.31 ± 0.07 1.04 ± 0.02 1.23 ± 0.14 0.97 ± 0.05^(A)Measurements taken before (pre-treatment) and 60 minutes after(post-treatment) Rx administration. ^(B)pooled data from saline controland control antibody (NTN) experiments

The effect of 10C12 on normal hemostasis was assessed by measuring thecuticle bleeding time, which has previously been shown to be coagulationdependent in dogs and rabbits. The bleeding time was measured before10C12 administration (pre-value) and at, the end of the experiment(post-value; 60 min after bolus administration). Despite its potentantithrombotic effect 10C12 did not prolong the cuticle bleeding time.Even at 1000 μg/kg the cuticle bleeding time remained unchanged (TableI). The effect of the highest dose of 10C12 (1000 μg/kg) on cuticlebleeding at an earlier time point was accessed in a separate group ofguinea pigs. In these experiments the cuticle bleeding time, incidenceof rebleeding and total blood loss were measured at 1 minute rather than60 minutes post treatment. As shown in Table II, there was a trendtowards an increase in these parameters in the 10C12 treated group.However, in no case was the increase statistically significant.Furthermore, in most cases (8 out of 9 in controls and 4 out of 6 in10C12 treated) bleeding ceased entirely after primary hemostasis wascomplete.

TABLE II Comparative effects of 10C12 antibody on cuticle bleeding inguinea pig and rat. Data are mean ± SEM Cuticle Total bleeding bloodSpecies Number of time^(A) Rebleed^(B) loss^(C) Rx Animals (mm) (number)(mg) guinea pig Control^(D) 9 3.1 ± 0.4 1 90 ± 21 10C12 - 1000 μg/kg 64.5 ± 0.7 2 137 ± 37  rat Control^(D) 10 2.5 ± 0.4 10 494 ± 105 10C12 -1000 μg/kg 10 2.6 ± 0.5 10 593 ± 197 ^(A)Measurements taken 1 minuteafter Rx administration ^(B)number of animals which have a cuticlebleeding episode after initial cesation of bleeding ^(C)total amount ofblood shed over 30 minutes (from cuticle transection) ^(D)pooled datafrom saline control and control antibody (NTN) experiments

Example 9

Administration of anti-IX/IXa gla Domain Antibodies Reduces Clot Weightand Duration of Vessel Occlusion in an, Arterial Thrombosis Model.

Methods

FeCl₃-induced arterial thrombosis model in the rat. The model of Kurz etal. (1990), Thromb. Res. 60:269–280, was modified as follows. Dosing andsampling catheters (PE 50 polyethylene tubing, Becton Dickinson and Co.,Sparks, ML) were placed in the femoral vein and artery of an isofloraneanesthetized, Sprague Dawley, male rat (Harlan Labs, Indianapolis,Ind.). Rat body weights ranged from 420 to 460 grams. Body temperaturewas maintained at 37° C. throughout the surgical and experimentalperiods. The carotid artery was dissected free of its surrounding tissueand a ultrasonic flow probe (Transonic IR, Transonic Systems Inc.,Itheca, N.Y.) was placed on the artery proximal to the heart. Thrombosiswas induced by placing a slit polyethylene tubing (PE 205) containing a3 mm diameter filter paper disc saturated with 70% FeCl₃ around theexposed artery cranial to the probe. Blood flow was monitored prior toand for 60 minutes following placement of the disc. 10C12, NTN orheparin were diluted to the appropriate concentration in sterile salinefor injection. Various doses of 10C12 or NTN were administered as asingle bolus of 1 ml. Heparin was administered as a loading bolus (100U/kg) followed by a constant infusion (1 U/kg/min) over 65 minutes(total volume of 2 ml). Controls for the heparin administrationconsisted of saline for injection administered over the same time periodand at the same volume. All treatments were administered via the venouscatheter 5 minutes prior to disc placement. At one minute (NTN and 10C12treatments) or 30 minutes (saline and heparin treatments) post dosingtail bleeding times were measured as described below. At 60 minutes, theartery was excised and any thrombus present was removed, blotted withfilter paper and weighed. Thrombosis endpoints recorded were theincidence and duration of occlusion, and thrombus weight. Blood sampleswere drawn from the arterial catheter at predose and at 1, 35 and 65minutes after dosing. These samples were analyzed for PT, APTT and ACTas described.

Measurements of tail bleeding time and blood loss in the rat thrombosismodel. Tail bleeding time was determined by a modification of the freehand tail transection method described by Dejana et al. (1982), Thromb.Haemostasis 48:108–111). During the experimental period the rat wasmaintained supine on an elevated platform such that its tail wasperpendicular to the plane of the body. Tail temperature was kept at 37°C. by placing it through the inner lumen of a water jacketed condenser(Kontes Glass, Baxter Healthcare Corp., Deerfield, Ill.) attached to athermostatically controlled water recirculator (American MedicalSystems, Cincinnati, Ohio). With this configuration, approximately 10 mmof the tail tip was accessible for transection. Tail bleeding times weremeasured following transection of 5 mm of the tail tip with a veterinarynail clipper (Resco model 727 with #400 blade, Tecla Co Inc, Walled LakeMich.). This procedure was performed at one minute (NTN and 10C12treatments) or 30 minutes (saline and heparin treatments) post dosing.These sampling times were selected to coincide with the time at whichblood concentrations of the test reagents and therefore hemostaticeffects were presumed to be near maximal for the bolus and infusionregimens used to administer the respective test reagents. Blood dropswere collected at 30 second intervals into a pre-weighed microfuge tube.Bleeding time was recorded as the time before bleeding was completelyarrested or drops required >30 seconds to form. At this time a secondtube was placed under the tail to collect any additional blood(secondary blood loss) that was shed for up to 30 minutes after the tailtransection. After this 30 minute collection period, the wound wascauterized to prevent additional blood loss. The total amount of bloodlost over 30 minutes was determined by summing the weight of bloodcollected in the two tubes.

Additional cuticle bleeding time and blood loss experiments in guineapig and rat. Because there were differences in how guinea pig cuticlebleeding and rat tail bleeding responded to 10C12 treatment, additionalbleeding measurements were performed in order to identify the source ofthe discrepancy. In these additional experiments, the same methodologywas used to measure bleeding in both guinea pigs and rats. Briefly, theanimals were anesthetized and dosing catheters placed as described inthe respective thrombosis models. However, blood samples, blood pressureor thrombosis measurements were not taken. One minute followingadministration of control (saline or NTN) or 1000 μg/kg of 10C12 as anIV bolus, the cuticle was transected and bleeding time, rebleeding andtotal blood loss where measured as described above for the rat tailbleeding assay.

Results

Antithrombotic and hemostatic effects of 10C12 and heparin in rat. Theeffects of 10C12 and heparin in the rat FeCl₃-induced arterialthrombosis model were examined. The antithrombotic efficacy was assessedby measuring the incidence and duration of vessel occlusion during the60 min period following application of FeCl₃. In addition, the weight ofthrombus recovered at the termination of the experiment was measured.Representative carotid artery blood flow tracings of a saline controland a 10C12 treated rat are shown in FIG. 13. Following bolusadministration of the control antibody (NTN at 2000 μg/kg) none of thethrombotic nor any of the hemostatic endpoints were significantlydifferent from the saline control. Therefore, saline and NTN controldata were pooled for subsequent comparison to 10C12 and heparintreatments. Occlusion occurred in 10 out of 10 control animals at anaverage time of 14.11.5 min. With the exception of one animal, in whicharterial flow briefly recovered before reoccluding, occlusion wassustained for the remainder of the experiment. The clot weight ofcontrols was 2.8±0.2 mg and the duration of vessel occlusion was44.7±2.6 min (FIG. 14). Administration of 10C12 at 500 μg/kg had noeffect on either parameter nor on incidence of occlusion (5 out of 5).At 1000 μg/kg the incidence of occlusion decreased to 2 out of 5 (P≦0.05vs control), while the clot weight was reduced to 0.66±0.17 mg(23.6±6.1% of control) and the duration of vessel occlusion decreased to9.6±8.9 min (21.5±19.9% of control) (FIG. 14). At the highest dose of2000 μg/kg, 10C12 further reduced the incidence of occlusion to 0 out of5 (P≦0.001 versus control), while average clot weight decreased to0.26±0.08 mg (9.2±2.3% of control) (FIG. 14). The effects on APTT/PT/ACTwere determined from measurements in blood samples taken prior to and atmultiple time points after drug administration. Since these parametersremained stable during the 60 minutes post dosing period, the 30 minutepost dose values were selected for comparison to the predose value.10C12 produced modest, dose dependent prolongation of the APTT and ACTwhereas the PT was not affected (Table III), demonstrating thespecificity of 10C12 in vivo. In comparison, administration of heparin(100 U/kg bolus and 1 U/kg/min infusion rate) had dramatic effects onthe APTT in addition to affecting the ACT and PT (Table III) withoutcompletely reducing the clot weight or restoring vessel patency (FIG.14).

TABLE III Effects of 10C12 antibody and heparin on coagulationparameters in rat plasma. Data are mean ± SEM Number APTT PT ACT ofprolongation prolongation prolongation Rx animals (post/pre)^(A)(post/pre)^(A) (post/pre)^(A) Control^(B) 10 1.00 ± 0.02  0.98 ± 0.01 0.90 ± 0.03  10C12  500 μg/kg 5 1.13 ± 0.14  0.97 ± 0.01  1.06 ± 0.02* 1000 μg/kg 5 1.23 ± 0.10  0.99 ± 0.01  1.14 ± 0.05** 2000 μg/kg 5 1.67 ±0.15** 0.97 ± 0.02  1.20 ± 0.09** Heparin 1 U/kg/min 5 12.1 ± 0.37**1.24 ± 0.09** 2.16 ± 0.13** ^(A)Measurements taken before and 35 minutesafter Rx administration. ^(B)pooled data from saline control and controlantibody (NTN) experiments *P = 0.05, **P = 0.01 (Mann-Whitney post hocafter Kruskal-Wallis Test)

As shown in table IV, none of the antithrombotically active doses of10C12 prolonged the tail bleeding time. However, major effects of 10C12on total blood loss were observed. In control animals, primaryhemostasis at the transected tail was complete after 2.0±0.3 min and theweight of blood collected during this time period was 31.1±9.4 mg. Incontrast to the transected guinea pig cuticle, all of the control tailwounds either continued to ooze blood (at a rate of less than one dropof blood per 0.5 minutes), or in some cases began to rebleedintermittently. In spite of oozing and/or resumed bleeding, the averageblood loss during this secondary period was small (57.1±32.0 mg)relative to the time period (mean=48 minutes) over which the blood wascollected. Administration of 10C12 exacerbated this secondary bloodloss, thus increasing the total blood loss (Table IV). Although animalto animal variation was considerable, secondary blood loss increased ina dose dependent manner and the increase was statistically significantat all of the doses tested. Primary blood loss was not significantlyaffected. Heparin also caused increased cumulative blood loss. However,in contrast to 10C12 this increased bleeding was primarily due todelayed hemostatic plug formation reflected in prolonged tail bleedingtimes and increased primary blood loss (Table IV).

TABLE IV Effects of 10C12 antibody and heparin on bleeding time andblood loss in the rat. Data are mean ± SEM Tail Primary Secondary TotalNumber of bleeding time^(A) blood^(B) loss blood^(C) loss blood loss^(D)Rx animals (min) (mg) (mg) (mg) Control^(E) 10 2.0 ± 0.3  31.1 ± 9.457.1 ± 32.0  88.2 ± 32.5  10C12  500 μg/kg 5 2.0 ± 0.4  78.8 ± 41  424 ±216*  503 ± 257  1000 μg/kg 5 2.3 ± 0.2  70.8 ± 25  473 ± 198** 544 ±209** 2000 μg/kg 5 2.6 ± 0.8  117 ± 67 558 ± 280** 674 ± 343** Heparin 1U/kg/min 5 16.5 ± 5.6**  319 ± 195 178 ± 77.2   497 ± 142**^(A)Measurements taken 1 minute after Rx administration ^(B)amount ofblood shed during bleeding time measurement ^(C)amount of blood shedafter cessation of initial bleeding to 30 minutes after tail transection^(D)total amount of blood shed over 30 minutes (from tail transection)^(E)pooled data from saline control and control antibody (NTN)experiments *p = 0.05, **p = 0.01 (Mann-Whitney post hoc afterKruskal-Wallis Test)

Rat cuticle bleeding. Because the pattern of blood loss following 10C12administration in the guinea pig cuticle and the rat tail were sodifferent, cuticle bleeding experiments were performed in a separategroup of rats. As in the rat tail bleeding experiments, oozing and orrebleeding occurred at the transected cuticle of both control andtreated animals (10C12 at a dose of 1000 μg/kg). However, in contrast tothe tail bleeding assay, 10C12 did not enhance secondary bleeding at therat cuticle, as there was no difference in cuticle bleeding time,incidence of rebleeding or total blood loss between control and 10C12treated animals (Table II).

1. An isolated antibody or antigen binding fragment thereof which: (a)specifically binds a factor IX/IXa Gla domain; and (b) comprises a heavychain and a light chain variable region further wherein: (i) the heavychain variable region comprises a CDR1 which is SEQ ID NO: 10, a CDR2which is SEQ ID NO: 11 and a CDR3 which is SEQ ID NO:12; and (ii) thelight chain variable region comprises a CDR1 which is SEQ ID NO: 13, aCDR2 which is SEQ ID NO:14, and a CDR3 which is SEQ ID NO:15.
 2. Acomposition comprising the antibody or antigen binding fragment of claim1 and a carrier, excipient or stabilizer.
 3. The composition of claim 2,wherein the carrier, excipient or stabilizer ispharmaceutically-acceptable.
 4. The composition of claim 3, which issterile.
 5. The composition of claim 4 further comprising a thrombolyticagent.
 6. The composition of claim 5 wherein the thrombolytic agent istissue plasminogen activator.
 7. The composition of claim 5 wherein thethrombolytic agent is streptokinase.
 8. The composition of claim 5wherein the thrombolytic agent is urokinase.
 9. The composition of claim5 wherein the thrombolytic agent is an isolated streptokinaseplasminogen.
 10. The composition of claim 4 which is lyophilized. 11.The composition of claim 4 which is liquid.
 12. The composition of claim5 which is lyophilized.
 13. The composition of claim 5 which is liquid.14. An article of manufacture comprising; (a) a container; (b) a labelon said container; and (c) a composition comprising an antibody orantibody fragment of claim 1 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 15. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 4 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 16. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 5 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 17. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 6 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 18. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 7 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 19. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 8 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.
 20. An article ofmanufacture comprising: (a) a container; (b) a label on said container;and (c) the composition of claim 9 within said container; wherein thecomposition is effective for treating a coagulation disorder, andoptionally a label on said container indicating that the composition canbe used for treating a coagulapathic disorder.